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Abstract 
Breast cancer is commonly associated with bone metastases, with 
approximately 70% of patients dying from breast cancer having radiological 
evidence of skeletal involvement. Median survival after diagnosis on bone 
metastases can be 2-3 years and therefore patients are at a high risk for the 
development of skeletal-related events. Consequently, research in both the 
laboratory and the clinic has addressed the potential for bone targeted 
agents to reduce the risk of developing skeletal metastases. The AZURE 
clinical trial is an international randomised phase III clinical trial that recruited 
3360 early breast cancer patients in which participants received either 19 
doses of zoledronic acid (ZOL) in 5 years or observation. No other clinical 
trial has undertaken such an intensive schedule of adjuvant 
bisphosphonates and therefore the safety and longer term sequelae were 
imperative to investigate should the drug become a standard of care. 
This thesis describes sub-studies undertaken in AZURE participants to 
investigate i) the incidence of osteonecrosis of the jaw (a recognised 
complication of bisphosphonates) and oral health-related quality of life and 
ii) a quantitative bone scanning technique to describe the effects the 
intensive schedule of zoledronic acid on bone remodelling and how this 
changes with time. Finally, the use of bone-related biomarkers (1,25-OH 
vitamin D, P1NP, CTX and 1CTP) measured in serum collected at baseline 
(before commencing zoledronic acid) have been investigated for their 
prognostic and predictive potential.  
 
- ix - 
The principal findings described in this thesis are: i) relatively low rate of 
osteonecrosis of the jaw (2.1%) with no significant impact or oral health r-
related quality of life; ii) patients with elevated bone turnover markers at 
baseline are at increased risk of bone metastasis but these markers cannot 
be used to identify patients who will benefit from zoledronic acid; iii) bone 
turnover continues to be significantly suppressed in the axial skeleton 2 
years after the cessation of zoledronic acid. The quality of the safety data 
presented in this thesis has contributed to the introduction of 
bisphosphonates into standard practice in the UK and across the globe. 
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Preface 
The work for this thesis commenced in 2010 thanks to the encouragement 
and support of Professor Robert Coleman, Chief Investigator of the 
international, randomised phase III trial AZURE, a study designed to 
determine whether adjuvant zoledronic acid with (neo)adjuvant 
chemotherapy and/or (neo)adjuvant endocrine therapy is superior to 
(neo)adjuvant chemotherapy and/or(neo)adjuvant endocrine therapy alone 
in improving the disease-free and bone metastasis-free survival of stage II/III 
breast cancer patients.    At the time, Professor Janet Brown was working in 
Leeds where I was an Academic Clinical Fellow in Medical Oncology 
exploring opportunities to undertake a higher research degree, preferably 
clinical research. She nurtured those interests and introduced me to 
Professor Coleman.  
In collaboration with the Clinical Trials Research Unit (Leeds) and The 
Cancer Clinical Trials Centre (Sheffield) I have become experienced in the 
design, conduct and analysis of clinical trials, translation medicine, 
laboratory techniques and the preparation of manuscripts for per-reviewed 
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1 Introduction 
1.1 Breast cancer 
1.1.1 Background 
Breast cancer is the most frequently diagnosed cancer among women in 
both the developed and developing world, representing 23% of all female 
cancers2-4. Within in the UK, there were nearly 55,000 new cases of female 
breast cancer and 11,433 deaths from female breast cancer in 20145. While 
incidence of breast cancer has increased for a number of reasons, survival 
is also improving, with around 85% of women in England surviving their 
disease for 5 years or more5.  
 
1.1.1.1 Pathology 
Malignant tumours of the breast are overwhelmingly of epithelial origin. This 
thesis will only deal with invasive breast carcinoma but it is acknowledged 
here that non-invasive states (ductal and lobular carcinoma in situ, DCIS and 
LCIS, respectively) and tumours arising from other tissues including 
lymphomas and sarcomas exist. The majority of invasive breast carcinomas 
are classified as invasive ductal carcinoma, not otherwise specified (NOS), 
comprising a heterogeneous group of tumours that do not exhibit sufficient 
characteristics to be otherwise histologically classified6. Less common types 
include lobular, tubular, mucinous, inflammatory and medullary carcinomas. 
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However, it is well-recognised that the heterogeneity of breast cancer goes 
far beyond the traditional pathological staging and grading systems, as 
evidenced by the great variation in clinical behaviour. A greater 
understanding of the underlying biology of the disease has enabled some 
explanation as to the varying nature of the disease and progress in this area 
continues to be made7. Now widely established, the oestrogen receptor (ER) 
and human epidermal growth factor receptor 2 (HER2) confer both 
prognostic and predictive value and are routinely examined on pathological 
specimens by either immunohistochemistry or fluorescence in situ 
hybridization (FISH). ER has been identified as a hormone-regulated nuclear 
transcription factor that is present in two forms, α and β. The binding of 
oestrogen induces the expression of a number of genes including the 
progesterone receptor (PR)8. This signalling pathway has been exploited for 
therapeutic benefit through the development of drugs that antagonise the 
binding of oestrogens. For example tamoxifen, a selective oestrogen 
receptor modulator (SERM) substantially reduces recurrence rates in the 
first 10 years following diagnosis (relative risk (RR) 0·53 during years 0–4 
and RR 0·68 during years 5–9; p<0·00001)9. The drug also reduces breast 
cancer mortality by approximately a third at 15 years follow up. Aromatase 
inhibitors (AIs) were later developed to inhibit peripheral oestrogen 
biosynthesis and provide an alternative in post-menopausal women and 
have shown superiority over tamoxifen. For example, a meta-analysis of AIs 
versus tamoxifen reported a disease recurrence absolute risk reduction of 
2.9% for the newer drugs in post-menopausal ER positive women in the 
adjuvant setting10. 
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The HER2 gene encodes a transmembrane tyrosine kinase receptor that is 
over expressed in 20-25% of breast cancers11. Over expression of the gene 
is associated with a number of oncogenic processes including cell 
proliferation, angiogenesis and reduced apoptosis12. The overexpression of 
the gene can be determined by immunohistochemistry performed on 
formalin-fixed paraffin-embedded tissue samples or, following equivocal or 
inconclusive results, FISH. Patients with HER2 positive breast cancer are 
considered to have a poorer prognosis, many clinical studies reporting HER2 
gene amplification as an independent prognostic factor, including patients 
with node negative disease12, 13. Like ER, HER2 is also a predictive marker, 
identifying patients who are likely to respond to targeted treatments. 
Trastuzumab is a monoclonal murine humanised antibody that binds to the 
extracellular portion of the HER2 receptor and is approved for treatment in 
both the adjuvant and metastatic setting.  Since the work described in this 
thesis commenced, new anti-HER2 therapies have been developed 
including pertuzumab (anti-HER2 humanised monoclonal antibody that 
inhibits receptor dimerization), trastuzumab emtansine (conjugate of 
trastuzumab with the microtubule inhibitory agent TDM1) and lapatinib (oral 
anti-HER2 and anti-HER1 tyrosine kinase inhibitor)14.  
 
Perou et al proposed that breast tumours could be further classified into 
molecular sub-types, including the separation of ER positive tumours, 
according to different gene expression profiles and that these correlate with 
different clinical outcomes15, 16. These 5 initial sub-types (basal, ERBB2+, 
luminal A, luminal B and normal) were determined by hierarchical clustering 
4 - 
on patterns of expression of over 500 genes showing that luminal A breast 
cancer patients had considerably longer survival outcomes compared with 
basal and ERBB2+ subtypes16, 17. The molecular sub-types have also been 
shown to respond differently to neoadjuvant chemotherapy in terms of 
pathological complete response rate (pathCR; 34% with triple negative 
tumours, 8% with low grade ER positive tumours)18. However, the molecular 
subtypes were not independent of more conventional predictors of response, 
including ER status. 
Assessment of molecular sub-types did not easily translate into routine 
clinical practice and therefore surrogate biological sub-types determined 
using standard immunohistochemistry markers (ER, PR, HER2, Ki67) were 
proposed19, 20. These sub-types have shown prognostic significance for OS 
and DFS in addition to predictive value for response to chemotherapy, and 
represent a convenient, if not identical, approximation19, 21. 
 
1.1.1.2 Staging 
Prognosis and management of breast cancer depends particularly on the 
stage of the disease (figure 1-1) in addition to other factors including 
histological grade, hormone receptor status, human epidermal growth factor 
receptor (HER2) status, menopausal status and co-morbidities22. Initial stage 
of disease is significant in terms of overall survival. For example, in England, 
more than 90% of patients with a stage I cancer are expected to live for 5 
years of more while this figure drops to around 50% for those diagnosed at 
stage III (figure 1-2)5. Asymptomatic distant metastases from breast cancer 
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are rare and therefore routine full radiological staging is not frequently 
undertaken. 
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Tx Primary tumour cannot be 
assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour ≤ 20 mm in greatest 
T1mi Tumour ≤ 1 mm in greatest 
dimension 
T2 Tumour > 20 mm but ≤ 50 mm 
in greatest dimension 
T3 Tumour > 50 mm in greatest 
dimension 
T4 Tumour of any size with direct 
extension to the chest wall and/or 
to the skin (ulceration or skin 
nodules 
* T1 includes T1mi 
** T0 and T1 tumours with nodal 
micrometastases only are excluded from Stage 
IIA and are classified Stage IB 
Figure 1-1 Breast cancer staging system (7th Edition TNM) AJCC  
Stage 0 Tis N0 M0 
Stage IA 
Stage IB 
T1* 
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T1* 
N0 
N1mi 
N1mi 
M0 
M0 
M0 
Stage IIA 
 
 
Stage IIB 
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Stage IIIC 
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T3 
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N2 
N2 
N1 
N2 
N0 
N1 
N2 
N3 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
Stage IV Any T Any N M1 
Nx Regional lymph nodes cannot be 
assessed 
N0 No regional lymph node 
metastases 
N1 Metastases to movable 
ipsilateral level I, II axillary lymph 
node(s) 
N2 Metastases in ipsilateral level I, II 
axillary lymph nodes that are 
clinically fixed or matted; or in 
clinically detected* ipsilateral internal 
mammary nodes in the absence of 
clinically evident axillary lymph node 
metastases 
M0 No clinical or radiographic 
evidence of distant metastases 
Mx Distant detectable metastases 
as determined by classic clinical and 
radiographic means and/or 
histologically proven larger than 0.2 
mm 
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Figure 1-2 Five-Year Relative Survival (%) from breast cancer by 
Stage, Adults Aged 15-99, CRUK website5 
 
 
 
1.1.1.3 Management 
Management of early stage breast cancer typically includes a combination of 
surgery, radiotherapy and systemic therapies, the latter comprising cytotoxic 
chemotherapy, endocrine treatments and other targeted drugs.  
 
1.1.1.3.1 Surgery 
In 2009 the British Association of Surgical Oncology (BASO) produced 
comprehensive guidelines on the surgical management of breast cancer 
which have been widely endorsed and adopted into local policy23. Regarding 
operable primary breast cancer, surgery aims to achieve local control of the 
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tumour and regional lymph nodes, either by mastectomy or breast-
conserving surgery (BCS) followed by adjuvant radiotherapy. Randomised 
trials confirm that survival outcomes for either approach are equivalent for 
tumours up to 2cm in maximum diameter, with no significant differences up 
to 22 years follow-up24-27. The surgical team must additionally assess the 
axillary lymph nodes, either by sampling, clearance or sentinel lymph node 
biopsy (SNB)23. SNB is often the preferred method for clinically node 
negative disease as it allows accurate assessment of the axilla with lower 
rates of morbidity28. 
 
Surgery does also play a role in the management of breast cancer that is not 
operable from the outset however, in the case of locally advanced disease, 
systemic therapy may be the most appropriate initial therapy. Where the 
disease is already metastatic at presentation, surgery is rarely indicated. 
 
1.1.1.3.2 Radiotherapy 
Radiotherapy plays an important adjuvant role in the management of early 
breast cancer. Women who have undergone BCS with clear margins require 
breast radiotherapy to reduce the risk of local recurrence. The Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) undertook a meta-analysis 
of 17 randomised trials of BCS alone versus BCS with adjuvant 
radiotherapy, reporting that radiotherapy reduces both the risk of local 
recurrence and the risk of death from breast cancer29. NICE guidelines also 
recommend offering chest wall radiotherapy to patients who are at high risk 
for recurrence for local recurrence (4 or more positive axillary lymph nodes 
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or involved resection margins). In addition, radiotherapy to the 
supraclavicular fossa should be offered if 4 or more positive axillary lymph 
nodes, or 1 – 3 positive axillary lymph nodes with another poor prognostic 
factor, such as a T3 or grade 3 tumour. This guidance is supported by the 
EBCTCG meta-analysis of  5-year local recurrence risks and mortality in 
8500 early breast cancer patients who underwent mastectomy and chest 
wall or regional lymph node radiotherapy30. Local recurrence rates and 
breast-cancer mortality rates were significantly reduced in the groups 
receiving radiotherapy (6% versus 23% and 54.7% and 60.1%, respectively).  
1.1.1.3.3 Systemic therapies 
Standard adjuvant systemic therapies for early breast cancer include a 
combination of traditional cytotoxic chemotherapy, hormonal therapy and 
biological agents and must take predictive and prognostic factors, 
menopausal status, side effects and performance status into account. 
 
Post-menopausal women with ER-positive disease should be offered 
treatment with an aromatase inhibitor (either anastrazole, exemestane or 
letrozole) unless considered low risk according to the Nottingham Prognostic 
Index (NPI; figure 1-3). Those considered at low risk should receive 
tamoxifen for 5 years. Premenopausal women should be offered tamoxifen 
in the first instance. However, NICE recommends that premenopausal 
women who have been offered chemotherapy, but declined it, may be 
offered ovarian ablation/suppression in addition to tamoxifen. 
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The treating clinician must make an estimate of benefit from cytotoxic 
chemotherapy based on the patient’s age and underlying prognosis. Tools 
are now available to assist in this decision such as Predict and Adjuvant! 
Online, calculating risk of relapse and death based on the EBCTGC meta-
analyses. More recently, gene expression profiles that can provide additional 
prognostic and/or predictive information are available. An anthracycline-
based regimen is used routinely, however taxanes (docetaxel) are now 
NPI = [0.2 x S] + N + G 
Where: 
S is the size of the index lesion in centimetres 
N is the node status: 0 nodes = 1, 1-4 nodes = 2, >4 nodes = 3 
G is the grade of tumour: Grade I =1, Grade II =2, Grade III =3 
 
Score 5-year survival 
>/=2.0 to </=2.4 93% 
>2.4 to </=3.4 85% 
>3.4 to </=5.4 70% 
>5.4 50% 
 
 
 
 
Figure 1-3  Nottingham Prognostic Index formula and 
interpretation1 
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recommended to be offered as part of the adjuvant regimen for patients with 
positive lymph nodes31. 
 
Finally, trastuzumab should be offered to women with HER2-positive early 
breast cancer following their other adjuvant therapies for 1 year, or until 
disease recurrence, unless there are significant cardiovascular 
contraindications, while the combination of trastuzumab and pertuzumab is 
now used in the neoadjuvant setting32.  
 
1.2 Normal bone physiology 
1.2.1 Composition of bone 
Bone is a highly specialised tissue combining rigidity for support and 
protection with a dynamic biological environment that allows for mineral and 
acid-base balance, blood forming and repair33. Additionally, it acts as a 
reservoir for numerous growth factors and cytokines. There are 2 types of 
bone: cortical and trabecular. Cortical bone is dense and solid, surrounding 
the inner bone marrow, while trabecular bone is a honeycomb-like network 
within the bone marrow compartment.  
At a cellular level, bone is composed of 3 main cell types: osteoblasts, 
osteoclasts and osteocytes. These cells lie within the osteoid, an organic 
matrix of collagen and non-collagenous proteins and inorganic mineral salt 
deposits.  
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1.2.2 Bone remodelling 
Bone constantly undergoes a process of remodelling in response to 
biomechanical forces, removing old, microdamaged bone (resorption) and 
replacing it with new, mechanically stronger bone (formation)33. This 
dynamic tissue is composed of an inorganic component and an organic 
matrix, largely comprised of collagen. Within the organic network, the 
primary bone cells, osteoblasts and osteoclasts, are constantly remodelling 
bone through this coupled process, allowing bone to meet its mechanical 
needs in addition to the regulation of calcium and phosphate homeostasis 
(figure 1-4). 
 
 
Figure 1-4  Drawing of bone remodelling34  
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1.2.2.1 Osteoclasts 
Osteoclasts are principally responsible for bone resorption and are closely 
related to macrophages, derived from mononuclear myeloid lineage. They 
are large, multinucleated cells found on the surface of bone with the unique 
capacity to degrade and remove bone. The process of resorption 
commences with the proliferation and differentiation of osteoclast 
precursors, allowing mature cells to fuse with and adhere to the bone 
surface, the site of bone resorption. Pits, or “basic multicellular units”, are 
formed on the bone surface35. The process of resorption itself involves the 
secretion of acidic substances and lysosomal enzymes followed by 
apoptosis. Their key role in the process of bone resorption makes 
osteoclasts a principal target for the treatment of resorptive bone diseases 
such as osteoporosis and metastatic bone disease. 
 
Regulation of osteoclasts begins with the recruitment and stimulation of 
osteoclast precursor in bone remodelling sites36. Several steps in the 
resorption process are under the influence of the Receptor Activator of 
Nuclear Factor κ-B (RANK), a member of the tumour necrosis factor (TNF) 
superfamily, found on the surface of osteoclast precursors, chondrocytes 
and mature osteoclasts37. The principal ligand for RANK, RANKL, is 
expressed by bone marrow stromal cells, activated T-cells and osteoblasts 
and is essential for promoting osteoclastogenesis, committing a precursor to 
the osteoclast phenotype38. The binding of RANKL to RANK induces 
osteoclast differentiation, fusion and formation of mature osteoclasts, 
increases their activity and blocks apoptosis. Osteoclasts are further 
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regulated by osteoblasts through the production of osteoprotegerin (OPG) by 
the latter cell. OPG, also a member of the TNF family, is the decoy receptor 
for RANKL, blocking the RANKL-RANK interactions and the aforementioned 
processes39. The RANK/RANKL/OPG pathway is an integral component of 
bone turnover, regulated by several cytokines and chemokines secreted 
within the bone microenvironment, including parathyroid hormone (PTH), 
interleukin-1 (IL-1), vitamin D derivatives and TNF-α40.  
 
1.2.2.2 Osteoblasts 
Osteoblasts, originating from mesenchymal stem cells of the bone marrow 
stroma, are the other key player in bone remodelling, forming new bone to fill 
the pits left by the osteoclasts. Osteoblast differentiation is promoted through 
the activation of the canonical Wnt signalling pathway, a branch of the 
ubiquitous wnt signalling system that is a key regulator of many 
developmental, physiological and pathological processes, including renewal 
of bone41-43. Activated through factors secreted by osteoclasts they lay down 
osteoid that becomes mineralized and results in new bone44. This bone 
formation process requires the osteoblast to secrete type I collagen, 
enzymes such as alkaline phosphatase (ALP) and non-collagenous proteins 
including bone sialoprotein (BSP)45. Eventually, some of these osteoblasts 
become embedded in the osteoid and mature into terminally differentiated 
osteocytes. Osteocytes form cytoplasmic extensions that play an important 
role in the regulation of bone remodelling in response to mechanical 
forces46. Any remaining osteoblasts undergo apoptosis47. 
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The osteoclasts, osteoblasts and osteocytes in combination with the 
mineralized matrix and other cell types comprise the bone microenvironment 
and is under the control of many local and systemic factors. In relation to 
Paget’s theory of metastasis, this environment provides a fertile “soil” for 
cancer cells, allowing them to survive, grow and expand48.  Tumour cells 
secrete a great variety of proteins that interact with the local cells and 
pathways, increasing resorption and releasing further growth factors into the 
system. This is turn feeds tumour growth in the so-called “vicious cycle”49. 
An understanding of these interactions is crucial to the development of bone-
directed therapies with many emerging treatments exploiting the vast array 
of potential targets50. 
 
1.2.3 Markers of bone turnover 
The processes bone resorption and bone formation release a number of 
measurable factors that give an indication of current status of bone turnover. 
They may be either by-products of the process or secreted by the principal 
cells involved.  
 
1.2.3.1 Bone resorption markers 
Many of the measurable bone resorption markers are collagen degradation 
products. Type I collagen is the predominant collagen in bone and is 
composed of a triple helix of two α1 chains and one α2 chain, with proline 
and hydroxyproline accounting for approximately 25% of the total amino acid 
residues51. Urinary hydroxyproline was one of the first biochemical markers 
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used to monitor bone resorption rates in humans and animals52. However, its 
value is significantly limited due to several other sources of the peptide in 
addition to bone resorption, such as diet and turnover of soft connective 
tissues. Furthermore, much of the free hydroxyproline from collagen 
degradation is oxidised in the liver, further decreasing its usefulness. 
Hydroxyproline is additionally affected by age and circadian rhythm, with its 
peak excretion after midnight53. 
 
Pyridinoline (PYD) and deoxypyridinoline (DPD) cross-linking amino acids of 
collagen are also excreted in the urine during bone resorption and can be 
assayed relatively easily by high performance liquid chromatography (HPLC) 
or enzyme-linked immunosorbent assay (ELISA), providing some value in 
research and clinical situations. For example, multiple myeloma (MM) 
patients have significantly higher levels of PYD and PDP compared to 
healthy adults (p<0.0001)54. PYD and PDP levels are not affected by dietary 
collagen or metabolic degradation53. However, while bone is the major 
reservoir of these molecules, the contribution from soft tissues does again 
lessen their accuracy and therefore their practical value55.  
 
N-terminal cross-linked telopeptide of type I collagen (NTX) and C-terminal 
cross-linked telopeptide (CTX) are peptides derived from bone collagen 
degradation.  The NTX peptide exists in α1 and α2 isoforms, with the latter 
primarily derived from bone56. The CTX peptide also exists in 2 isoforms, α 
and β, the latter primarily derived from bone. Assays developed using an 
antibody specific for the NTX α2 chain can measure levels in either urine or 
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serum, however the urinary results must be adjusted for urinary dilution. The 
precision of the CTX assay to detect measurements lower than 200µg/L is 
poor so serum or plasma samples are preferable55. Urinary NTX levels are 
able to identify individuals with bone metastases across a number of 
different tumour sites57, 58. Perhaps clinically more useful however, is the 
ability of bone marker data to provide valuable prognostic information, which 
has been evaluated across many tumour sites. For example, high levels of 
urinary NTX in patients with bone metastases secondary to prostate cancer 
are indicative of an increased relative risk (RR) for disease progression (RR 
= 2.2; 95% CI 1.48, 2.74; p<0.001) and death (RR = 4.59; 95% CI 2.82, 
7.46; p<0.001)59. NTX and CTX are bone-specific and therefore not affected 
by diet, however are affected by circadian rhythm. 
 
C-telopeptide cross-linking domain of type I collagen (1CTP), released 
during collagen degradation, can also be detected in the serum by 
immunoassay, correlating well with bone resorption60. 1CTP is released by 
the action of matrix metalloproteinases (MMPs) and current assays are 
insensitive to physiological changes in bone turnover, such as those induced 
by oestrogen55. Similar to the above markers, serum 1CTP does also display 
a circadian rhythm, with levels 20% higher between the hours of 0200 -
055060.  
 
Tartrate-resistant acid phosphatase type 5b (TRAP 5b) is a specific marker 
for osteoclast number and activity that can be analysed in serum samples61. 
Expressed in high amounts by osteoclasts following attachment to the bone 
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surface, TRAP 5b is released into the circulation where it is inactivated and 
degraded. Therefore, catalytically active levels of the circulating enzyme 
reflect recently released enzyme as a result of bone resorption55. Methods 
have been developed to measure only the intact, active TRAP 5b, producing 
consistent results that correlate strongly with other bone markers61. 
 
1.2.3.2 Bone formation markers 
Prior to the assembly of a triple helix, collagen is synthesised in a precursor 
form as procollagen, containing polypeptide extensions at both its amino (N-) 
and carboxy (C-) terminal ends62. Proteases then cleave these extensions, 
allowing the triple collagen molecules to spontaneously assemble into 
collagen fibres. The cleaved fragments, procollagen type I N-propeptides 
(P1NP) and procollagen type 1 C-propeptide (P1CP) are released into the 
system and can reflect osteogenesis. Both P1CP and P1NP can be 
analysed in serum by either ELISA or radioimmunoassay (RIA)53. While both 
molecules are considered indices of collagen synthesis and thus bone 
formation, it is suggested that P1NP has greater diagnostic validity than 
P1CP63. 
 
Alkaline phosphatase (ALP) is a ubiquitously expressed, membrane-
associated enzyme originating from various tissues64. In healthy adults the 
bone alkaline phosphatase (BALP) isoform accounts for about 50% of total 
serum ALP63. BALP is produced by osteoblasts in high amounts during bone 
formation and therefore is an excellent indicator of total bone formation 
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activity. It is likely that the enzyme participates in the mineralisation process, 
with BALP activity proportional to the inorganic phosphate concentration60. 
 
Osteocalcin (OC) is another marker commonly used as an indicator of bone 
formation and is the major non-collagenous protein found in bone. In 
addition to being produced by osteoblasts and found in significant amounts 
in bone, it is produced by odontoblasts and hypertrophic chondrocytes and 
consequently also found in dentin and calcified cartilage, as well as 
malignant tissues63. However, most of the circulating OC originates from the 
bone as a product of osteoblastic activity. Interestingly, OC levels may 
reflect overall bone metabolism because it becomes incorporated into the 
bone matrix, allowing fragments to be released during the resorption process 
in addition to during osteogenesis55, 63. OC can be analysed in serum 
however its value is limited by OC-lipid binding impairing detection at high 
lipid values while the existence of multiple isomers in the circulation causes 
further problems for current assays55. OC can also be measured in urine as 
an index of bone turnover65. 
 
1.2.3.3 Regulators of bone turnover 
In addition to the RANK/RANKL/OPG triad mentioned previously, there are a 
number of other key players in the regulation of bone turnover. Bone 
sialoprotein (BSP) is a phosphorylated glycoprotein, which accounts for 12% 
of the non-collagenous matrix protein of bones and is a member of the small 
integrin-binding ligand N-linking glycoprotein (SIBLING) family. BSP (as well 
as other glycoproteins such as osteonectin and osteopontin) plays a role in a 
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number of aspects of bone metabolism, for example the control of 
mineralisation in the formation of new bones and bone resorption. BSP 
contains an Arg-Gly-Asp (RGD)-sequence, which is essential for the 
attachment of cells to bone surfaces 66. BSP has important functions in the 
initiation of hydroxyapatite-crystallisation, and in the interaction between 
bone cells and the mineralised bone matrix. BSP can be detected in 
mineralising connective tissue, where the osteoblasts are primarily formed. It 
has however also been detected in trophoblasts and to a lesser extent in 
decidua cells. BSP can be measured in the serum by immunoassay, 
however results so far have been difficult to reproduce and validate with 
commercially available kits. 
 
Parathyroid hormone (PTH) controls the homeostasis of calcium by direct 
action on the bone and kidney and an indirect action on the gut33. PTH, 
secreted by the parathyroid gland, stimulates bone resorption at high doses 
through its action on osteoblasts to induce osteoclastogenesis, while at 
intermittent doses it stimulates bone formation. 
 
1, 25 (OH) vitamin D is necessary for normal growth of the skeleton and 
calcium and phosphate metabolism. 80-90% is derived by the action of ultra-
violet B (UVB) sunlight on the skin resulting in cholecalciferol (D3)67. The 
remainder is derived from dietary sources (animal D3 or plant-derived 
ergocalciferol, D2). 25-hydroxylation takes place in the liver while further 1-
hydroxylation occurs in the kidney, resulting in the active metabolite, 1.25 
(OH) vit D. Mediated through the vitamin D receptor (VDR, steroid hormone 
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nuclear receptor superfamily), vitamin D has direct effects on bone 
resorption through induction of RANKL expression in osteoblasts, stimulating 
osteoclastogenesis68, 69.  
 
Cathepsin K is a protease that is highly expressed by osteoclasts and is 
primarily responsible for the degradation of the proteinaceous bone matrix. 
Cathepsin K therefore has a critical role in bone resorption and in recent 
times has become a drug target for metabolic bone diseases including 
malignant bone disease. The expression of cathepsin K is predominantly 
regulated by RANKL, as well as vitamin D, PTH, TNF and interleukins70. 
 
1.3 Bone health in breast cancer 
1.3.1 Cancer treatment-induced bone loss (CTIBL) 
The rate of bone loss increases with age, with the lifetime risk of a fragility 
fracture (hip, spine, distal forearm) without preventative treatment almost 
40% for women older than 50 years71. Due to the critical role that oestrogen 
plays in the maintenance of bone mass in women, the substantial hormonal 
changes around the menopause result in an imbalance in bone 
remodelling72. For example, in the 3 years following the cessation of 
menstruation, net bone loss at the lumbar spine is 2-5% annually, slowing to 
0.5% per year thereafter72. Many cancer survivors are at increased risk of 
bone loss due to their cancer treatment. As survival of patients with early 
breast cancer improves due to detection and the emergence of new 
therapies, the long-term implications of the various treatments has gathered 
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interest and importance. Many women can expect to live decades beyond 
their initial diagnosis but may be living with consequences of their cancer 
management. It is now widely recognized that cancer treatment-induced 
bone loss (CTIBL) is a complication of both hormonal and cytotoxic 
chemotherapies, affecting pre- and post-menopausal women. 
 
Pre-menopausal levels of circulating oestrogen are known to be fundamental 
in the maintenance of normal bone mass in women73.  The transition from 
pre-menopausal to post-menopausal sees significant hormonal changes with 
the loss of ovarian follicular activity, including a fall in circulating 
oestrogens74. The oestrogen-deficient environment present after menopause 
results in an imbalance in bone remodelling with a net loss of bone mass73. 
Therefore, breast cancer survivors are at risk of bone loss due either to 
temporary amenorrhea or premature menopause from cytotoxic 
chemotherapy, reversible ovarian suppression or treatments to reduce 
circulating oestrogen levels, particularly third-generation aromatase 
inhibitors (AIs).  
 
1.3.1.1 Cytotoxic ovarian failure 
Cytotoxic cancer therapies can induce premature menopause and 
secondary amenorrhea in 25-100% of women receiving adjuvant treatment 
for breast cancer75. Women older than 40 years at the time of chemotherapy 
are at greatest risk of induced ovarian failure, and consequently of BMD 
decline76. Premenopausal women receiving cyclophosphamide, 
methotrexate and 5 fluorouracil (CMF) chemotherapy experience 
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menopause on average 10 years earlier than normal controls with a 
significant impact on their BMD77. Most studies have investigated 
premenopausal women receiving a cyclophosphamide-containing regimen, 
commonly CMF, which is known to directly affect ovarian reserve in relation 
to age at treatment and cumulative dose. One such study reports that, where 
menstruation is preserved throughout chemotherapy, BMD is also 
maintained up to 5 years at the lumbar spine (LS) and femoral neck (FN) 
after initial treatment, with changes from baseline of -1.3% and -0.3% 
respectively78. That is compared to significant losses at LS of -10.4% and FN 
of -5.8% in patients who became amenorrhoeic. It has been suggested that 
loss of ovarian function is not the sole cause of BMD declines in women 
undergoing adjuvant chemotherapy following a small study that reported 
mean losses in BMD were not significantly different between those who lost 
and those who maintained ovarian function 6 months after initial treatment79. 
Loss in ovarian function during chemotherapy has been confirmed by a 
number of groups as detrimental to bone health76, 80-82. The investigators 
suggest that during the administration of chemotherapy there may be a 
direct cytotoxic effect of chemotherapy on bone cells. However, after 
completion of chemotherapy, changes are related to ovarian function. 
 
1.3.1.2 Hormonal manipulation 
Aromatase inhibitors (AIs) 
AIs are now widely considered the drug of choice for adjuvant oestrogen 
blockade in post-menopausal patients with hormone-receptor positive 
tumours due to their improved efficacy and favourable side effect profile 
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compared with tamoxifen. Aromatase converts androgens to oestrogens, the 
main source of endogenous oestrogen in post-menopausal women. In the 
adjuvant setting, all licensed third-generation AIs have demonstrated BMD 
declines which raises concern for osteoporosis and skeletal complications. 
This is the case whether upfront AI or a switch after 2-3 years of tamoxifen is 
used. For example, the large Arimidex, Tamoxifen, Alone or in Combination 
(ATAC) trial randomized post-menopausal women to adjuvant tamoxifen or 
anastrazole reporting significantly improved disease-free survival outcomes 
in the group receiving the AI83. A bone sub-study which assessed BMD at 
baseline, 1, 2 and 5 years after commencing treatment showed significant 
losses at the LS and total hip (TH) in the AI group (-6.08% and -7.24% 
respectively) compared with modest gains in the tamoxifen group (+2.77% 
and +0.74%, respectively)84. This loss did not continue after the cessation of 
treatment85. The Intergroup Exemestane Study (IES) which randomized 
post-menopausal women to either 5 years of tamoxifen or a switch to 
exemestane after 2-3 years observed that this loss of BMD in the AI group 
did translate to more fractures compared with the tamoxifen only group (7% 
versus 5%; p=0.003)86, 87. However, 2 years after completion of treatment, 
the exemestane group partially recovered bone loss (+1.53% at LS and 
stabilization at TH) while the tamoxifen group saw a decline in BMD 
following the withdrawal of the drug (-1.93% at LS and -2.62% at TH)88.  
 
Of note in these studies and others, the comparison group receives 
tamoxifen which has been observed to exert moderate protective effects 
against bone loss in post-menopausal women, compounding the negative 
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effect observed in the AI groups89-91. Tamoxifen is a selective oestrogen 
receptor modulator which can exert either oestrogen antagonistic effects (for 
example breast tissue) or agonistic effects (e.g. in the vasculature or 
bone)92. In contrast, tamoxifen has been associated with BMD losses in 
premenopausal women. It has been suggested that tamoxifen causes bone 
loss in pre-menopausal women by exerting an oestrogen antagonistic effect 
on bone in the presence of pre-menopausal oestrogen levels89, 93. 
 
LHRH analogues 
LHRH analogues such as goserelin can be used for temporary ovarian 
suppression in the adjuvant management of premenopausal women. The 
Zoladex Early Breast Cancer Research Association (ZEBRA) study 
assessed the efficacy and tolerability of goserelin versus CMF in pre-
menopausal women with node-positive breast cancer, observing 
equivalence comparing the 2 groups for hormone-receptor positive breast 
cancer94. At 2 years follow-up in a bone sub-study, BMD losses in the 
goserelin group were significantly greater than the chemotherapy group at 
both the lumbar spine (-10.5% versus -6.5%) and femoral neck (-6.4% 
versus -4.5%)95. One year after cessation of goserelin, however, there were 
no significant differences between the 2 groups due to partial recovery in the 
goserelin arm. Ovarian suppression was associated with BMD in both 
groups. 
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1.3.2 Treatment of CTIBL 
1.3.2.1 Bisphosphonates 
Mechanism of action 
Bisphosphonates are a class of anti-resorptive drugs that have become 
established in routine clinical practice for both benign and malignant bone 
disease. They are stable synthetic analogues of pyrophosphate with a P-C-P 
backbone that allows avid binding to hydroxyapatite on the bone surface96. 
The presence of a nitrogen atom on one of two covalently attached side 
chains generally separates bisphosphonates into 2 classes, either the more 
potent nitrogen-containing BPs (N-BPs; such as zoledronic acid) or those 
with less potent anti-resorptive activity, the non-nitrogen agents, including 
clodronate96, 97. The 2 classes differ in their mechanisms of action. Non N-
BPs are actively taken up by osteoclasts and metabolised to analogues of 
adenosine triphosphate (ATP) which consequently leads to osteoclast 
apoptosis. N-BPs, however, act through inhibition of the mevalonate 
pathway, blocking farnesyl diphosphate synthase (FPPS; figure 1-5). This 
results in a lack of required intermediates for the prenylation of signalling 
GTPases, including Ras, Rho and Rac, ultimately causing osteoclast 
dysfunction and apoptosis. In addition, the accumulated isopentyl 
diphosphate (IPP) is metabolised to a cytotoxic, intracellular ATP analogue, 
triphosphoric acid I-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester 
(Apppi)98. Apppi inhibits mitochondrial ADP/ATP translocase, causing loss of 
mitochondrial membrane potential and direct induction of osteoclast 
apoptosis. Furthermore, Apppi stimulates γδ T cells, thus modulating the 
immune system99. 
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Figure 1-5 The mevalonate pathway. This pathway has a central role in 
cell metabolism producing isoprenoids that are incorporated into many 
essential end products  
 
 
Safety and toxicity of zoledronic acid 
The acute phase response is one of the most common side effects of 
zoledronic acid. This is an acute systemic inflammatory reaction 
characterised by fever, arthralgia and muscle pains, with or without nausea 
and oedema100. This usually develops within 48 hours of administration and 
is short-lived and self-limiting. 
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Metabolic effects of zoledronic acid include hypocalcaemia, affecting 9-39% 
of patients100. Whilst usually mild and transient, it is widely recommended 
that clinicians prescribe calcium and vitamin D supplements to prevent 
hypocalcaemia. Other electrolyte disturbances include hypomagnesaemia 
and hypophosphataemia and it is recommended that their levels are 
monitored during treatment.  
Renal toxicity is a concern with zoledronic acid treatment, however 
significant nephrotoxicity is rare. Following intravenous administration, the 
drug is predominantly excreted unchanged by the kidneys and some 
transient effects may be observed on renal function. To minimise the risks, 
serum creatinine should be measured prior to each infusion, in addition to 
ensuring adequate hydration, dose-reducing in patients with pre-existing 
renal impairment and delaying treatment in the presence deteriorating renal 
function101. 
 
Osteonecrosis of the jaw (ONJ) is a rare but serious complication of 
bisphosphonate therapy, first reported more than a decade ago by oral 
surgeons who noted painful exposed bone of the mandible, maxilla or both, 
in patients who had received intravenous bisphosphonate102, 103.  They 
report predominantly on cases in malignant disease and note that while the 
cancer may be under control, patients have poor quality of life due to their 
oral complications, with patients complaining of difficulty speaking, eating 
and performing oral hygiene. Neither antibiotics, surgical treatments nor 
hyperbaric oxygen proved effective treatments. The initial proposed 
underlying mechanisms included the anti-angiogenic effect of 
29 - 
bisphosphonates and the reduced bone turnover making the jaws vulnerable 
to the external environment. 
 
Since those initial reports, a great deal has been published regarding ONJ. 
The American Association of Oral and Maxillofacial Surgeons (AAOMS) 
position paper states that a confirmed case of ONJ must fulfil 3 critical 
characteristics: 1) current or previous bisphosphonate treatment; 2) an area 
of exposed bone in the maxillofacial region that has not healed within 8 
weeks after identification, and  3) no history of radiotherapy to the 
craniofacial region104. Symptoms frequently occur at the site of a previous 
tooth extraction but may appear spontaneously. Patients may present with 
localised pain, soft tissue swelling, inflammation, loosening of teeth and 
exposed bone. Expert panels have come together to provide 
recommendations on the prevention, diagnosis and treatment of ONJ.  
 
In their position paper, the AAOMS adopted the staging system proposed by 
Ruggiero104, 105. This describes 3 stages of disease: 
 
Stage 1.  Disease characterised by exposed bone that is asymptomatic 
with no evidence of any significant adjacent or regional soft 
tissue inflammatory swelling or infection. 
Stage 2. Disease characterised by exposed bone with associated pain, 
with adjacent or regional soft tissue inflammatory swelling or 
secondary infection. 
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Stage 3. Disease characterised by exposed bone with associated pain, 
adjacent or regional soft tissue inflammatory swelling or 
secondary infection that is difficult to manage with oral or 
intravenous antibiotic therapy. 
 
Following their 2009 update, the AAOMS added stage 0, to include patients 
with “no clinical evidence of necrotic bone, but present with nonspecific 
symptoms or clinical or radiological findings”106. This conflicts with their 
definition requiring exposed bone and has called into question whether 
exposed bone is required to confirm a case of ONJ or in fact earlier 
identification may facilitate more rapid management, and presumably more 
favourable outcome107, 108. Either way, it is acknowledged that little is known 
about the early features of ONJ and the risk for progression to more 
advanced states of the condition, calling for more research into “stage 0” 
patients. The AAOMS definition and staging system remain those currently 
accepted in the field.  
 
The underlying pathophysiology of ONJ remains poorly understood. 
Ruggiero outlines 4 principal theories: osteoclast-mediated bone remodelling 
suppression; anti-angiogenesis; local mucosal toxicity and, genetics109. The 
significant suppression of bone remodelling mediated by osteoclast inhibition 
is the most widely accepted theory and has obtained recent support from the 
observation that other potent osteoclast inhibitors, in particular denosumab, 
can lead to ONJ. It is suggested that the effect of these drugs is greater in 
the jaw due to the higher basal rate of bone turnover in this region. 
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Bisphosphonates have been demonstrated as potent inhibitors of 
angiogenesis. In vitro, zoledronic acid inhibits the proliferation of human 
endothelial cells in addition to modulating their adhesion and migration 
properties110.  Potent inhibition of angiogenesis has additionally been 
demonstrated in mice systemically administered zoledronic acid110. Should 
the vascular supply become compromised, a minor injury is at greater risk of 
developing into a non-healing wound with the potential to progress to 
necrosis and osteomyelitis. Additional support for this theory comes from the 
increased risk of ONJ when bisphosphonates and anti-angiogenic drugs are 
administered in combination111-114.  Furthermore, there are reports of ONJ in 
patients treated with anti-angiogenic compounds (bevicizumab) alone115, 116. 
It is postulated that high concentrations of bisphosphonate may accumulate 
in the jaw bone causing direct toxicity to the oral mucosa with consequent 
failure to heal and secondary osteomyelitis117. Preclinical studies have 
demonstrated direct toxicity to oral cell lines118-120. However, in clinical 
practice the accumulation of sufficient levels to be directly toxic to the oral 
epithelium is unproven. 
Finally, underlying pharmacogenetic factors may have a significant role in 
the pathophysiology of ONJ. Sarasquette et al identified a single nucleotide 
polymorphism in the cytochrome P450-2C gene that was associated with a 
significantly higher risk of ONJ development in a series of myeloma patients 
treated with bisphosphonate121. However, this finding was not validated in a 
further study122. Despite this, genetic susceptibility remains an attractive 
theory permitting new insights into the underlying mechanisms at play in the 
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occurrence of ONJ and the prediction of its development based on a genetic 
marker an appealing prospect123. 
Numerous risk factors for the development of ONJ have been identified and 
outlined in the AAOMS 2009 paper and for the purposes of this review have 
been summarised as a table.  
Drug-related factors Bisphosphonate potency (zoledronic acid versus 
pamidronate) 
Route of administration (increased risk with i.v. 
versus oral) 
Duration of therapy (longer duration associated 
with increased risk) 
Local factors Dentoalveolar surgery (including extractions, 
dental implant surgery, periodontal surgery with 
osseous injury) while on bisphosphonates 
increases risk 
Local anatomy (increased risk mandible versus 
maxilla; thin mucosa overlying bony 
prominences; concomitant oral disease e.g. 
dental abscesses) 
Demographic factors Age (increasing risk with increasing age) 
Race (increased risk Caucasian versus black) 
Tobacco use increases risk 
Genetic factors Increased risk with single nucleotide 
polymorphisms in cytochrome P450-2C gene 
Table 1-1  Table of risk factors for ONJ, summarised from AAOMS 2009 
Position Paper106 
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In light of these known risk factors, a number of preventative measures are 
now routinely recommended. Dental examination before the first 
administration of BP is important to identify any required treatment and 
healing before the commencement of therapy. Additionally, patient education 
regarding dental hygiene and reporting of oral symptoms have contributed to 
a reported decrease in zoledronic acid-related ONJ124, 125. It is 
recommended that dental procedures should be avoided on BP therapy with 
consideration given to withholding treatment for any invasive treatments to 
take place. 
 
Clinical trials of BPs in CTIBL 
Bisphosphonates are established for the treatment of benign and malignant 
bone disease. In the cancer setting they are used to prevent skeletal 
complications of bone metastases such as fracture and spinal cord 
compression97. As anti-resorptive drugs with confirmed efficacy in the 
osteoporotic setting, several clinical trials have investigated their role in 
preventing CTIBL. 
 
The oral bisphosphonate clodronate was amongst the first to be investigated 
in this setting. Saarto et al randomized post-menopausal women receiving 
tamoxifen or toremifene with or without clodronate for 3 years, observing 
increases in BMD at the LS (+2.9%) and femoral neck (+3.7%)126. In a more 
recent study including pre- and post-menopausal women, the benefits of 
clodronate were confirmed, with LS BMD 1.92% higher and TH BMD 1.29% 
higher in the clodronate group compared with the placebo group127. While 
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compliance with medication has been a concern around oral 
bisphosphonates due to the their gastrointestinal side effects, clinical trials 
investigating both ibandronate128 and risedronate129-131 have similarly shown 
efficacy in preventing CTIBL. 
 
The intravenous bisphosphonate zoledronic acid (ZOL) has been shown 
across a range of studies to prevent bone loss in both pre- and post-
menopausal women. In a pre-menopausal population, 6-monthly (ZOL) has 
been shown to reverse the bone loss induced by a combination of goserelin 
plus tamoxifen or anastrazole. In this study (ABCSG-12), the mean loss of 
bone in the lumbar spine over 3 years in the absence of a bisphosphonate 
was -11.3% while 2 years after the cessation of endocrine treatment, BMD 
was still significantly lower than baseline at -6.3%. However, BMD was 
protected following administration of 6-monthly zoledronic acid with values 
remaining stable over time132. 
Three studies have specifically addressed upfront ZOL versus delayed 
treatment if osteoporosis or osteopenia occurs in postmenopausal women 
receiving the AI letrozole133-135. The Z-FAST study investigated 602 ER 
positive post-menopausal breast cancer patient receiving adjuvant letrozole 
who were randomised to wither delayed or upfront ZOL, 4mg intravenously 
every 6 months for 5 years. The ZO-FAST study was of similar design in 
1065 patients and finally the E-ZO-FAST study with 527 patients. All 3 
studies observed higher BMD measurements in the upfront group compared 
with the delayed group. The Z-FAST study, which has the most mature data, 
reported at 5 years follow up the mean difference in LS and total hip BMDs 
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between the upfront and delayed groups was 8.9% and 6.7%, 
respectively133. However, despite this positive effect on BMD, no significant 
difference in fracture rates has yet been demonstrated.  
 
1.3.2.2 Denosumab 
Denosumab is a relatively new anti-resorptive agent that has been 
investigated to protect against AI-induced bone loss. A fully humanised 
monoclonal antibody against receptor activator of nuclear factor-kappaB 
ligand (RANKL), denosumab blocks the interaction between RANKL and its 
receptor on osteoclasts, the binding of which would usually activate and 
maintain osteoclast-mediated bone resorption. In a 2 year double-blind, 
randomized controlled trial of denosumab versus placebo, osteopaenic 
postmenopausal women on an AI had significant gains in the denosumab 
arm at the LS compared with placebo136. 
 
While results from these studies are encouraging in terms of preserving 
skeletal health, no systemic treatments are approved to prevent CTIBL. A 
number of guidelines exist for patients at risk that generally require 
assessment of BMD at baseline with follow-up scans and advice regarding 
calcium, vitamin D and lifestyle changes. A recent economic evaluation has 
given support to this approach in terms of fracture prevention137. The impact 
of lifestyle certainly has its place with a few small studies observing that 
regular resistance and weight-bearing activity can result in modest gains in 
BMD in addition to influencing bone turnover markers138-140. Baseline vitamin 
D levels are also of importance with sufficient supplementation shown to 
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improve BMD and reduce risk of fracture141, 142. With the majority of new 
breast cancer patients reported to have insufficient or deficient levels of 
vitamin D, perhaps they are even at risk of bone loss and subsequent 
fracture before any treatment is commenced. 
 
1.4 Breast cancer and bone metastases 
1.4.1 Scope of the problem  
1.4.1.1 Patterns of disease 
Many patients with advanced cancer will develop metastatic bone disease 
accounting for considerable morbidity. The propensity for spread to bone 
varies depending on the primary site of disease, however breast, prostate 
and lung cancer account for approximately 80% of all bone metastases143. 
With these being the 3 most common cancers in the U.K. the burden of 
disease from skeletal involvement is substantial144. Consequently, the 
prevention and management of bone metastases is an important component 
of research and clinical agendas. Bone is the most frequent site of distant 
relapse among breast cancer patients, accounting for around 40% of all first 
distant recurrence and around 70% patients with advanced breast cancer 
develop bone metastasis145. 
 
Breast cancer patients in whom bone is the first site of metastasis have 
significantly better outcomes than those in whom the first site is the liver 
(median survival 2 years versus 3 months; p<0.001)146. Similarly, if disease 
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remains confined to the skeleton, median survival is 2.1 years versus 1.6 
years if extraosseous sites are involved (p<0.001)147. Favourable outcomes 
for patients with “bone-only” disease has been confirmed in more recent 
studies148-150. 
 
1.4.1.2 Skeletal-related events 
While women with bone-only metastatic disease may have a prognosis 
measured in years, the potential complications of bone metastases, so-
called skeletal-related events (SREs), can have a considerable impact of 
their lives. SREs include pathological fracture, spinal cord compression, 
hypercalcaemia and the need for radiotherapy or surgery to bone. Without 
bone-targeted therapy, a patient with bone metastases can experience up to 
an average of 4 SREs per year151. Zoledronic acid, amongst other 
bisphosphonates, has been investigated for its role in patients with bone 
metastases and is now established as standard treatment in this patient 
group to reduce frequency of SREs, improve bone pain and slow 
progression of disease in the bones. In a randomised, double-blind phase III 
trial of zoledronic acid versus pamidronate, zoledronic acid reduced the risk 
of SREs by 20% compared with pamidronate (2 years follow up; p=0.025)152. 
A meta-analysis comprising 21 bisphosphonate trials conducted in advanced 
breast cancer patients with bone metastases (BP versus placebo or other 
BP) reported that zoledronic acid provides the greatest risk reduction for 
SREs (HR 0.59; 95% CI 0.42- 0.82)153. The meta-analysis concludes that 
BPs, either i.v. or p.o. reduce the risk of developing a SRE, reduce the rate 
of SREs and increase the time to first SRE. The study reached no firm 
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conclusions regarding the optimal time to initiate treatment with a BP or the 
appropriate duration, an area that remains unconfirmed. However, an 
exploratory analysis of the above zoledronic acid study did show that if BP is 
administered before the onset of bone pain, outcomes may be improved154.  
The question around timing of initiation of BP may be in part resolved by 
identifying high risk individuals for SREs. Bone turnover markers have been 
investigated in this role. Breast cancer patients with a high level of the 
resorption marker NTX   have a 3-fold increased risk for an SRE, in addition 
to poorer progression-free survival and mortality155. If the marker is 
normalised during treatment with zoledronic acid, patients experience 
significantly lower risk for  first SRE and improved survival156, 157. While no 
marker of bone metabolism currently is able to definitively predict clinical 
outcomes in individual patients, there are emerging markers, including BSP 
and RANKL, which show encouraging results and warrant further 
investigation in the setting of clinical trials55. 
Recently, endocrine therapy has been combined with cyclin-dependent 
kinase (cdk) 4 and 6 inhibitors (palbociclib, ribociclib, abemaciclib) in 
advanced breast cancer with very promising results and are now NICE 
approved in the first line metastatic setting in combination with an aromatase 
inhibitor. For example, palbociclib combined with letrozole in advanced 
breast cancer demonstrated significant increased medical progression-free 
survival compared with letrozole plus placebo (24.8 months versus 14.5 
months; p<0.001158). On subgroup analysis, a few studies have suggested a 
particularly promising role for the combination of cdk 4/6 inhibitors with 
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endocrine therapies amongst patients with bone-only disease at baseline 
and it may be that they have an emerging role in this specific population159.  
 
1.4.2 Underlying mechanism of bone metastasis 
Tumour invasion into bone is associated with the recruitment of osteoblasts 
and osteoclasts, resulting in the release of growth factors from the bone 
matrix which further enhance tumour growth, the so-called “vicious cycle”160, 
161. The differentiation and activation of osteoclasts and osteoblasts result in 
increased bone turnover, a process to which the aforementioned RANK-
RANKL-OPG triad is key. Additionally, the presence of tumour in the bone 
microenvironment modulates platelet function, myeloid cells, immune cells, 
nerve cells and angiogenesis50. This specific variety of cell types provides a 
fertile soil for the attraction and survival of cancer cells. Cancer cells are able 
to inhabit the bone marrow, acting as a reservoir for dormant cells that may 
be able to resist cytotoxic therapy and either emerge later as full-blown bone 
metastases or seed to other sites162.  
Whether a tumour spreads to bone or not is likely related to factors 
expressed by the primary tumour, its local environment and the metastatic 
site. The pre-metastatic niche refers to the concept that the primary tumour 
is able to prepare sites of metastasis50. For example, breast cancer cells can 
secrete osteopontin, promoting bone marrow cell recruitment163. Determining 
some of these factors when a patient initially presents would allow clinicians 
to make rational decisions regarding management and follow up. 
Tumour cells that metastasise to bone can use the same physiological 
mechanism as those employed by haematopoetic stem cells homing to 
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bone. Chemokines and their receptors play a critical role in this process. 
Muller et al were among the first to investigate the similarities between 
tumour cell migration to preferential sites and leukocyte trafficking164. They 
demonstrated that the chemokine receptor CXCR4 is strongly expressed on 
the cell surface in breast cancer cell lines and primary breast cancer cells 
and that CXCR4 mRNA was significantly upregulated in primary breast 
tumours compared with normal mammary tissue. Furthermore, the ligand for 
CXCR4, CXCL12, is expressed preferentially in bone, lymph nodes, liver 
and lungs. Finally they showed that neutralising the CXCR4/CXCL12 
interactions significantly impaired metastasis of breast cancer cells. There 
are a few small clinical studies that suggest the primary tumour cells exploit 
this homing mechanism, however most are retrospective and of moderate 
size165-167. This mechanism has attractive therapeutic potential with some 
cell line work demonstrating that treatment of MDA-MB 231 inoculated mice 
with a CXCR4 antagonist can decrease the metastatic burden, though not 
the incidence of metastasis168. 
 
1.4.2.1 Prognostic and predictive markers 
Some specific, conventional histopathological features have been 
associated with primary tumour preference for bone as a site of metastasis 
including low tumour grade, ER positivity and lymph node involvement147, 169-
171. Using immunohistochemistry to identify more novel markers of relapse in 
bone has so far failed to discover anything well-validated and robust enough 
to use either in clinical practice or stratify patients entering clinical trials. A 
proteomics discovery platform identified two novel biomarkers, macrophage-
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capping protein (CAPG) and PDZ domain-containing protein (G1PC1), from 
primary breast tumours172. This revealed that co-expression of these two 
markers in primary tumours was prognostic for development of bone 
metastases and predictive of benefit from adjuvant zoledronic acid in women 
with early breast cancer. Furthermore, investigation of the transcription 
factor MAF has demonstrated some potential as a predicative marker173. In 
patients with MAF-negative tumours, zoledronic acid was associated with 
higher invasive-disease-free survival than was control treatment (HR 0·74, 
95% CI 0·56–0·98), but not in patients who had MAF-positive tumours. In 
fact, in this study, patients who were MAF positive experienced detrimental 
effects of zoledronic acid if they were not postmenopausal at the time of 
treatment.  
 
Attempts at identifying a serum marker that predicts for bone metastasis 
development have also resulted in some interesting results however none so 
far reliable to move into clinical practice. In 1999 Diel et al used a 
radioimmunoassay to analyse serum BSP levels in 388 pre-operative breast 
cancer patients. With a median follow up of 20 months, Serum BSP was an 
independent prognostic factor for the development of skeletal metastases on 
multivariate regression analysis (p,0.001)174. Unfortunately, this work has 
never been reproduced. More recently, marker measurements in a couple of 
randomised, prospective clinical trials have shown some promise. Firstly, a 
subgroup analysis of a randomised, double-blind placebo-controlled trial of 
standard therapy with or without clodronate for 2 years suggested that early 
changes in P1NP levels was associated with the likelihood of developing 
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bone metastases127. 230 of these patients had P1NP levels analysed at 
baseline and at 1 year. Those with an increase in P1NP, termed 
“progressive”, had higher rates of subsequent bone metastasis (20.8%) 
compared with those who had a decrease, or “responsive” (6.3%) or stable 
levels (7.8%; p=0.011). A second adjuvant phase III breast cancer trial 
measured pre-treatment βCTX levels in 621 primary breast cancer patients 
who were receiving tamoxifen with or without octreotide175. With a median 
7.9 years follow up, elevated serum βCTX levels were associated with 
shorted bone-only recurrence-free survival. Further work is required to 
establish whether any of these, or other markers, can reliably identify 
patients at high risk of subsequent bone metastases and to enable their 
appropriate management. 
 
Employing modern genetic techniques has allowed genes to be identified 
that are differentially expressed between those that metastasise to bone and 
those that do not. Smid et al gene mapped the primary tumours from 107 
breast cancer patients who experienced a relapse and identified 69 genes 
that were significantly differentially expressed between those with bone 
metastasis versus other disease of metastasis176. Several others have 
attempted similar work however the results are largely non-conclusive. While 
we are gaining an increased understanding of factors associated with 
osteotropism, there is still no validated, reliable marker to predict elevated 
risk of subsequent bone metastases177. 
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1.4.3 Does Adjuvant Zoledronic acid reduce recurrence in 
patients with high-risk, localised breast cancer? (AZURE 
clinical trial) 
The AZURE trial was a prospective, randomised, open-label phase III trial 
designed to determine the role of ZOL 4mg i.v. combined with (neo)adjuvant 
chemotherapy and/or endocrine therapy in stage II/III breast cancer patients. 
The primary objective was to determine whether ZOL with chemotherapy 
and/or endocrine therapy was superior to chemotherapy and/or endocrine 
therapy alone in improving DFS. Secondary objectives were to determine 
superiority of the combination in terms of: 
 Invasive disease-free survival (IDFS) 
 Time to bone metastasis as first recurrence 
 Time to bone metastasis per se 
 Time to distant metastasis 
 Overall survival 
 Reducing SREs prior to and following bone metastasis 
development 
The trial design and follow up are shown in figure 1-4 and the trial synopsis 
in available in appendix 1.  
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Figure 1-6   Basic schema of main AZURE study. 
Full eligibility criteria available in Appendix 1. 
 
The rationale behind the addition of the bisphosphonates to adjuvant therapy 
was based on pre-clinical and clinical evidence of their anti-cancer activity. 
In-vitro studies show that N-BPs inhibit adhesion, migration and growth of 
breast cancer cells in addition to inducing apoptosis97. Further to this a 
sequence dependent synergy has been demonstrated in cell line work and in 
animal models. The combination of N-BP and anti-cancer drugs including 
doxorubicin more effectively suppresses metastases than either drug alone. 
Interestingly, sequential treatment with doxorubicin followed by ZOL 
produced a significant inhibition of tumour growth compared to ZOL followed 
by doxorubicin, simultaneous administration or either treatment alone. 
 
At the time of writing the protocol, 3 clinical trials had investigated clodronate 
in the adjuvant setting with conflicting results (table 1-2)178-180.  
45 - 
Study Number of 
participants 
Intervention Chemotherapy Results 
Saarto T et 
al 2001 
299 Clodronate 
1600mg daily for 
3 years versus 
observation 
All received 
chemotherapy 
(CMF) 
Development of bone metastases; clodronate 
versus control: 21% vs. 17%, p=0.27 
Development on non-skeletal metastases; 
clodronate versus control: 43% vs. 25%, 
p=0.0007 
Diel IJ et al 
1998 
302 (all with 
tumour cells 
present on 
bone marrow 
aspirate) 
Clodronate 
1600mg daily for 
2 years versus 
observation 
Varying; only 80 
patients received 
adjuvant 
chemotherapy 
Development of bone metastases; clodronate 
versus control: 8% vs. 17%, p=0.003 
Development on non-skeletal metastases; 
clodronate versus control: 8% vs. 19%, p=0.003 
Powles T et 
al 2002 
1069 Clodronate 
1600mg daily for 
2 years versus 
observation 
All received 
chemotherapy 
(CMF or EC) 
Development of bone metastases; clodronate 
versus control: 12% vs. 15%, p=0.127 
Development on non-skeletal metastases; 
clodronate versus control: 21% vs. 24%, 
p=0.257 
Table 1-2  Table summarising adjuvant clodronate clinical trials
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A meta-analysis of these 3 studies concluded that the addition of clodronate 
probably does not improve outcome for patients181. It was hoped that the 
increased potency of ZOL would have beneficial effects compared to 
clodronate in terms of inhibition of bone resorption and reduction in growth 
factors and cytokines in the bone marrow microenvironment, but also 
through direct effects on tumour cells in the bone marrow. The overall 
results, however, did not show any advantage for the addition of ZOL to 
(neo)adjuvant therapy compared with standard therapy. At a median follow-
up of 59 months, there was no significant difference in the primary end point, 
with a rate of disease-free survival of 77% in each group (adjusted hazard 
ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI], 0.85 to 
1.13; P=0.79). Rates of overall survival of 85.4% in the zoledronic acid group 
and 83.1% in the control group were also not significantly different (adjusted 
hazard ratio, 0.85; 95% CI, 0.72 to 1.01; P=0.07). Intriguingly, a protocol-
defined sub-group analysis according to menopausal status did reveal 
significant heterogeneity of treatment effect. Patients who had gone through 
the menopause 5 or more years previously had improved IDFS with ZOL 
compared with standard treatment alone (78.2% versus 71.0%; HR 0.75CI, 
0.59 to 0.96; P = 0.02) and improved 5-year overall survival (84.6% in the 
zoledronic acid group and 78.7% in the control group (adjusted hazard ratio, 
0.74; 95% CI, 0.55 to 0.98; P = 0.04). Since the work described in this thesis 
was completed, a further publication has updated the efficacy data, 
demonstrating that there is continued reduction in occurrence of bone 
metastases at any time with zoledronic acid (HR 0.81, 0·68-0·97; p=0·022) 
and improved IDFS in those who were over 5 years since menopause at trial 
47 - 
entry (n=1041; HR 0·77, 95% CI 0·63-0·96)182. The role of reproductive 
hormones in the efficacy of bisphosphonates as anti-cancer drugs is now 
being investigated. 
 
To conclude, the AZURE clinical trial, with its large and robust dataset of 
clinical information and samples for translation studies, provided a major 
opportunity to further the study of multiple factors affecting bone metastasis 
and the role of zoledronic acid in the adjuvant setting. Much of this thesis 
takes advantage of that significant opportunity. Chapter 2 investigates the 
occurrence of osteonecrosis of the jaw in patients within the AZURE study, 
dental health-related adverse events and oral health-related quality of life. 
The Oral Health Impact Profile-14 is used to compare oral health-related 
quality of life in patients who received zoledronic acid with those on 
observation. Chapter 3 utilises the blood samples collected for translational 
studies to identify prognostic markers in addition to markers predictive for 
benefit from zoledronic acid. The markers investigated as P1NP, CTX, 1CTP 
and vitamin D. Chapters 4 and 5 describe a novel quantitative bone 
scanning technique used to investigate the impact of 5 years of zoledronic 
acid on bone turnover in addition to serum markers of bone turnover and 
bone density data. 
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2 Osteonecrosis of the jaw and oral health-related quality 
of life in early breast cancer patients receiving adjuvant 
zoledronic acid 
2.1 Background 
The work considered in this chapter has been published in the Journal of 
Clinical Oncology183. I undertook the literature search of various tools for 
measuring oral health-related quality of life, suggested additional questions, 
analysed the data and undertook all statistical analysis in this chapter, with 
the exception of producing cumulative incidence frequency for osteonecrosis 
of the jaw. Additionally, I undertook site visits to confirm cases of ONJ and 
reviewed all reported cases. 
 
The association between bisphosphonate and ONJ has been outlined in 
Chapter 1. Following the initial reports of the association in 2003-2004102, 184, 
the AZURE clinical trial patient information sheet was revised to highlight this 
possible risk and all patients already participating were required to re-
consent. The trial protocol was amended to exclude patients with significant 
active dental problems or recent oral surgery. Dental hygiene advice was 
distributed to all patients while investigators were provided with guidance on 
diagnosis, prevention and treatment of ONJ. The AZURE trial collected 
detailed information on suspected and confirmed ONJ which allows direct 
comparison between the control arm and the ZOL arm.  
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The safety of administering zoledronic acid alongside chemotherapy has 
already been reported185. In addition to the known risk of ONJ, this safety 
report also identified more frequent dental adverse events (AEs) among the 
patients receiving zoledronic acid compared with the control group. 
However, it is unknown what impact zoledronic acid has on patients’ quality 
of life, specifically in relation to their oral health and the potential subclinical 
manifestations that may not be identified during routine oncology follow up.  
  
2.1.1 Measuring oral health-related quality of life 
The World Health Organisation (WHO) defines health as a “state of 
complete physical, mental and social well-being, not merely the absence of 
disease or infirmity”186. Therefore, one cannot assume that purely providing 
curative treatment for breast cancer returns a patient to full health and that a 
more holistic approach must be adopted to monitor and manage the impact 
of the diagnosis and treatment on the individual. With that in mind, the 
assessment of patient’s quality of life is also significant and has more 
recently been formally incorporated into clinical trials. The European 
Organisation for Research and Treatment of Cancer (EORTC) Study Group 
on Quality of Life identified the need for an integrated measurement system 
for evaluating the quality of life of patients participating in international 
clinical trials187. Since their initial questionnaire EORTC QLQ-C36 in 1987, 
numerous tools have become available for measuring health-related quality 
of life directed at increasingly more specific patient populations. 
A need to assess oral health-related quality of life (OH-QoL) was similarly 
identified by dentists and oral health surgeons resulting in a proliferation of 
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tools to investigate the quality of life of patients with various oral conditions. 
There are several definitions of OH-QoL in the published literature but one of 
the most common is that described by Locker as “the symptoms and 
functional and psychosocial impacts that emanate from oral diseases and 
disorders”188. Many early tools were criticised for reflecting the values of 
health care professionals rather than patient concerns. Therefore, 
questionnaires were developed from in-depth, qualitative interviews with the 
target population. The patient survey that we chose, the Oral Health Impact 
Profile-14, is now one of the most widely used tools in the published 
literature with evidence for its use across many different populations 
worldwide including large national population studies189. Its purpose is to 
assess the dysfunction, discomfort and disability caused by oral 
conditions190. In its development, 535 statements were obtained from 
qualitative interviews with 64 dental patients. This was reduced to a set of 49 
unique statements to represent the 7 domains of oral health as outlined in 
Locker’s conceptual model: 
 
 functional limitation 
 physical pain 
 psychological discomfort 
 physical disability 
 psychological disability 
 social disability 
 handicap 
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 Following the publication of the initial 49 item questionnaire, Slade derived 
and validated a shorter survey with only 14 questions as it was identified that 
many research settings did not permit the use of the full 49 item 
questionnaire191. This OHIP-14 allows 2 statements per domain and each 
question within the domain carries a weighting and has been found to have 
good validity, reliability and precision (full questionnaire available in 
appendix 2). 
 
2.1.2 OH-QoL among patients with/at risk of ONJ 
As mentioned previously, the reporting of ONJ has become a formalised 
requirement of clinical trials investigating bone-targeted agents such as ZOL 
and denosumab and consequently there has been rigorous assessment of 
patients oral health. Nevertheless, there remains minimal information on 
what this impact has on OH-QOL. Most of the reports focus on pain and 
general health-related quality of life (H-QoL). For example, a trio of parallel 
randomised phase III studies conducted in patients with bone metastasis 
from solid tumours or myeloma comparing 4-weekly ZOL with 4-weekly 
denosumab prospectively collected data on ONJ, H-QoL, using Functional 
Assessment of Cancer Therapy survey, and pain, using Brief Pain Inventory-
Short Form4. However, it is not known what impact ONJ, or other dental AEs 
related to the study drugs, had on OH-QoL.  
Two small studies have retrospectively investigated OH-QoL in patients with 
known ONJ. The first in a cohort of 34 patients with confirmed ONJ 
associated with bisphosphonates,  using the OHIP-14, reported that ONJ 
causes a significant decline in OH-QoL192. However, there is no comparison 
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with patients who did not develop ONJ whilst receiving bisphosphonates. 
The second study compared patients with confirmed ONJ and metastatic 
breast cancer, metastatic breast cancer with no known ONJ and patients 
with cancer of the oral cavity but no ONJ193. They used the EORTC-C30 and 
QLQ-HN35 (head and neck specific) questionnaires.  
Our study, reported in detail below, has already been published 183 and at 
the time of this work is the only study that investigates the OH-QoL in 
patients receiving bisphosphonate treatment compared with patients who 
received no bisphosphonate treatment183. 
2.2 Aims of study 
To describe the occurrence of ONJ in early breast cancer patients treated 
with standard therapy plus adjuvant ZOL and the outcomes of confirmed 
cases. 
To describe the occurrence of dental AEs in early breast cancer patients 
treated with standard therapy plus adjuvant ZOL versus patients who 
received standard therapy alone. 
To investigate OH-QoL in early breast cancer patients treated with standard 
therapy plus adjuvant ZOL versus patients who received standard therapy 
alone. 
 
Endpoints of the study are: 
 The safety and toxicity of ZOL in this clinical setting with regard to 
dental AEs and occurrence of ONJ. 
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 Dental heal domain scores as derived from OHIP-14 questionnaire. 
2.3 Methods 
2.3.1 Patients 
2.3.1.1 Patient population for ONJ assessments 
All patients within the main AZURE study were required to have 
histologically-confirmed breast cancer with axillary node metastasis or a 
T3/T4 primary tumour. Patients were randomly assigned to receive either 
standard adjuvant therapy (control arm) or standard adjuvant therapy plus 
19 intravenous administrations of ZOL 4mg over 5 years (see figure 1-1). All 
patients received oral supplements of calcium and vitamin D for the first 6 
months and then continued thereafter at the local investigator’s discretion. 
Following the emergence of a potential link between bisphosphonates and 
ONJ, the protocol was change to mandate clinical review of the oral cavity 
and questions regarding any dental problems at every clinic visit, in addition 
to dental hygiene advice distributed to all patients on study. 
 
2.3.1.2 Patient population for OH-QoL sub-protocol 
486 (control, n=242; ZOL 244; see CONSORT diagram figure 2-1) AZURE 
trial participants from centres within the U.K. who recruited at least 10 
patients to the main AZURE and were not involved in another AZURE sub-
study, were invited to take part in the OH-QoL sub-protocol between 
February and November 2010. Eligibility criteria required patients to be 4.5 – 
5.5 years past their randomisation date at the time of questionnaire 
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completion. This was to coincide with either final ZOL administration on 
study patients or similar follow up time point in control patients. Patients 
were ineligible if they had developed bone metastases as this might have 
produced symptoms affecting results. 
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Analysed for time from 
randomisation 
 n = 175 
Excluded from analysis( n=1) 
owing to incomplete 
questionnaire 
Analysed for last 1 month 
n = 172 
Excluded from analysis( n=4) 
owing to incomplete 
Approached to participate in 
Oral-QOL sub-protocol (n = 242) 
 176 returned 
questionnaire 
Allocated to control arm 
(n=1679) 
Approached to participate in 
Oral-QOL sub-protocol (n = 244) 
 186 returned 
Randomized in 
AZURE 
(n=3360) 
Allocated to receive zoledronate 
(n=1681) 
Analysed for time from 
randomisation 
 n = 185 
Excluded from analysis (n=1) 
owing to incomplete 
questionnaire 
Analysed for last 1 month 
n = 184 
Excluded from analysis (n=2) 
owing to incomplete 
Figure 2-1   CONSORT diagram to show eligible and consented patients for the main 
AZURE study and OH-QoL sub-protocol. 
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2.3.2 Study design 
Study design of the main AZURE study has been described in the 
introduction with further detail available in the protocol synopsis found in the 
appendix 1. 
 
2.3.3 Oral-QoL questionnaire design and data collection 
The study was designed as a one-off survey using the OHIP-14 
questionnaire. Participants were asked to complete two identical 
questionnaires; the first to relate to their experience over the past one month 
and the second time to relate to their overall OH-QoL experience since 
randomisation. This was to separate out the time when all patients may have 
been receiving chemotherapy and steroids (which could in itself cause poor 
OH-QoL, for example from mucositis or oral infections), from time when only 
the study group were receiving ZOL but the control group receiving no 
intravenous anti-cancer therapy. Patients were asked to answer additional 
questions regarding their oral health that may influence OHIP-14 scores (see 
questionnaire in Appendix 2).  
Responses to OHIP-14 questions were coded on a 5-point ordinal scale (0 = 
never, 1 = hardly ever, 2 = occasionally, 3 = fairly often, 4 = very often). 
Severity scores were calculated as the sum of all responses (maximum 
severity score = 56). Prevalence scores were represented as the percentage 
of participants responding with “fairly often” or “very often”. 
Missing values were substituted by the mean for the specific item from the 
appropriate arm. The sensitivity of this approach was checked by 
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substituting the maximum and minimum possible values and re-running the 
analysis and ensuring that there was no significant difference in results. If 
more than 2 items were missing, the questionnaire was excluded from the 
analysis. 
Participants provided informed consent by completing and returning the 
questionnaire. Approval from the appropriate ethical committee was 
obtained before patients were approached for the study (in appendix 3). 
 
2.3.4 Statistical design 
2.3.4.1 Analysis of ONJ incidence 
Each case of reported ONJ underwent central review by clinical researcher 
(E Rathbone) including undertaking site visits to review clinical notes. The 
time to onset of ONJ was investigated using cumulative incidence function 
curves in which deaths without a diagnosis of ONJ were considered 
competing risk events. Additionally, each case is described descriptively in 
terms of number of ZOL administrations before diagnosis, median time to 
onset of ONJ from randomisation, site of ONJ and outcome. Date of onset of 
ONJ is defined as the date recorded by the local investigator of symptoms 
likely related to ONJ. Dental AEs are also reported descriptively according to 
CTC grading. This analysis was performed using SAS software, version 9.2 
(SAS Institute, Cary, NC). 
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2.3.4.2 Sample size calculation   
To allow an effect size of 0.3 to be detected between the 2 arms with a 5% 
(two-sided) significance level and 80% power using a two-sample t test of 
equal means 280 patients would be required to complete the questionnaire. 
A response rate of 50% was assumed. According to Cohen’s operational 
definitions this would relate to detecting a small to medium difference in OH-
QoL194.  
 
2.3.4.3 Analysis of OH-QoL 
Mean severity scores were analysed for each treatment group with 95% C.I. 
obtained from a multivariable linear regression model adjusting for the 
following potential prognostic factors: age (at time of survey), smoking, 
dentures, and pre-existing dental conditions or procedures (missing teeth, 
numbers of tooth extractions or other surgical dental procedures, and the 
frequency of dental visits). Mean domain scores were calculated by the 
same linear regression model adjusting for the same prognostic variables. 
Additionally, an ad hoc analysis was carried out adjusting severity scores for 
the occurrence of dental AEs.  Prevalence scores and dental AEs are 
reported descriptively. These analyses were performed using SPSS 
statistical software (PASW Statistics 17.0; SPSS, Chicago, IL). 
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2.4 Results 
2.4.1 Occurrence of ONJ 
The median follow up time from randomisation to time of analysis was 73.9 
months (interquartile range, 60.7 – 84.2 months). During this time, 33 cases 
of suspected ONJ were reported, all in the ZOL arm. 26 of these have been 
centrally confirmed as cases of ONJ according to the AAOMS position paper 
definition. This equates to a cumulative incidence rate of 2.1% (95% C.I., 
0.9% - 3.3%; see figure 2-2). Each case is described in table 2-1. Seven of 
the reported cases did not meet the criteria to be confirmed as cases of 
ONJ. 
 
Figure 2-2   Time to confirmed ONJ for patients randomly assigned to 
ZOL.  
Previously published, Rathbone et al
183
. 
 
60 - 
The median number of zoledronate administrations before the onset of ONJ 
in confirmed cases was 13 (range, 1 – 19). The median time from 
randomisation to onset of ONJ in confirmed cases was 863 days (range, 21 
– 2767 days). 85% of the confirmed cases (n=22) were known to have 
occurred following a dental extraction. Site of ONJ was confirmed in 25/26 
cases. Of the 25, 16 cases involved the mandible (64%), 12 the maxilla 
(48%). Three cases involved both sites therefore these figures calculate to 
>100%. 
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Case 
Age at 
onset 
No. Zol 
administrations 
Time from 
randomisation to 
onset (days) Site Extraction 
Outcome (days to complete recovery, or to 
date of analysis if not completely 
recovered) 
1 58 17 1780 Mandible Yes Completely recovered (420) 
2 62 13 879 Maxilla Yes Completely recovered (985) 
3 40 8 481 Mandible Yes Improving 
4† 63 13* 1712 Maxilla unknown Present and unchanged 
5† 51 16 1508 Maxilla Yes Present and unchanged 
6 68 14 1029 Mandible and maxilla Yes Improving 
7† 63 10* 840 Mandible unknown Unknown 
8 58 15 1132 Unknown unknown Improving 
9 54 8 636 Mandible Yes Present and unchanged 
10 54 1 21 Mandible Yes Recovered with sequelae 
11 42 11 647 Mandible Yes Completely recovered (615) 
12 54 8 363 mandible and maxilla Yes Completely recovered (650) 
13 39 11 670 Maxilla Yes Present and unchanged 
14 55 19 1915 Maxilla Yes Improving 
15 67 12 714 mandible and maxilla No Recovered with sequelae 
16 68 11 672 Mandible Yes Recovered with sequelae 
17 55 14 1364 Mandible Yes Present and unchanged 
18 55 11 364 Maxilla Yes Completely recovered (542) 
19 72 13 807 Mandible Yes Present and unchanged 
20 65 16 1455 Mandible Yes Present and unchanged 
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21 54 7 369 Mandible Yes Completely recovered (1271) 
22 46 14 846 Mandible Yes Completely recovered (914) 
23 47 18 1904 Maxilla Yes Improving 
24 46 18 1689 Maxilla Yes Completely recovered (280) 
25 59 19 2767 Maxilla Yes Present and unchanged 
26 52 13 988 Mandible Yes Completely recovered (1553) 
Table 2-1  Table of all 26 confirmed cases of ONJ 
†These patients have relapsed and continued a bisphosphonate off study. *Number of ZOL infusions on study prior to onset
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The outcomes of the confirmed cases were: completely recovered, n=9; 
recovered with sequelae, n=3; condition improving, n=5; condition present 
and unchanged, n=8; outcome not known, n=1.  
No case of suspected or confirmed ONJ was reported in the control arm 
(p<0.001).  
 
2.4.2 Oral-QoL 
2.4.2.1 Patient characteristics 
362 patients of the 486 invited AZURE participants returned a completed 
questionnaire (control, n=176, response rate 72.7%; ZOL, n=186, response 
rate 76.2%. See CONSORT diagram in figure 2-2). The baseline 
characteristics were very similar between the total AZURE population and 
the questionnaire responders (table 2-2). The assigned arm of study did not 
influence response rates as these are very similar between the groups. 
Dental characteristics of those who completed a questionnaire are displayed 
in table 2-3. The mean age at time of completing the questionnaire was 57 
years in both groups (control arm, range 36 – 79 years, SD 9.3 years; ZOL 
arm, range 38 – 79 years, SD 9.1 years). 
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 Main AZURE study 
population 
Oral QoL sub-study 
population 
Characteristic Zoledronic 
Acid 
Control Zoledronic 
Acid 
Control 
Axillary lymph nodes – no. (%) 
0 
1-3 
≥4 
Unknown 
 
29 (1.7) 
1041 (61.9) 
604 (35.9) 
7 (0.4) 
 
32 (1.9) 
1032 (61.5) 
608 (36.2) 
6 (0.4) 
 
4 (2.2) 
126 (67.7) 
55 (29.6) 
1 (0.5) 
 
2 (1.1) 
125 (71.0) 
49 (27.8) 
0 (0) 
Tumour stage – no. (%) 
T1 
T2 
T3 
T4 
TX 
 
542 (32.2) 
851 (50.6) 
227 (13.5) 
58 (3.5) 
3 (0.2) 
 
523 (31.2) 
867 (51.7) 
228 (13.6) 
59 (3.5) 
1 (0.1) 
 
67 (36.0) 
88 (47.3) 
28 (15.1) 
2 (1.1) 
1 (0.5) 
 
70 (39.8) 
87 (49.4) 
17 (9.7) 
2 (1.1) 
0 (0) 
Oestrogen-receptor status – no. 
(%) 
Positive 
Negative 
Unknown 
 
 
1319 (78.5) 
349 (20.8) 
13 (0.8) 
 
 
1316 (78.4) 
355 (21.2) 
7 (0.4) 
 
 
161 (86.6) 
24 (12.9) 
1 (0.5) 
 
 
144 (81.8) 
30 (17.0) 
2 (1.1) 
Menopausal status – no. (%) 
Premenopausal 
Postmenopausal 
≤5 yr 
>5 yr 
Status unknown 
 
751 (44.7) 
 
247 (14.7) 
519 (30.9) 
164 (9.8) 
 
752 (44.8) 
 
244 (14.5) 
522 (31.1) 
160 (9.5) 
 
83 (44.6) 
 
28 (15.1) 
56 (30.6) 
18 (9.7) 
 
71 (40.3) 
 
31 (17.6) 
56 (31.8) 
18 (10.2) 
Planned systemic therapy – no. 
(%) 
Endocrine therapy alone 
Chemotherapy alone 
Endocrine plus 
chemotherapy 
 
 
76 (4.5) 
362 (21.5) 
1243 (73.9) 
 
 
75 (4.5) 
360 (21.5) 
1243 (74.1) 
 
 
9 (4.8) 
24 (12.9) 
153 (82.3) 
 
 
2 (1.1) 
30 (17.0) 
144 (81.8) 
Planned type of chemotherapy – 
no./total no. (%) 
Anthracyclines 
Taxanes 
 
 
1567/1605 
(97.6) 
390/1605 
(24.3) 
 
 
1564/1603 
(97.6) 
385/1603 
(24.0) 
 
 
174/177 
(98.3) 
9/177 (5.1) 
 
 
167/174 
(96.0) 
13/174 
(7.5) 
Timing of chemotherapy – 
no./total no. (%) 
Neoadjuvant 
Postoperative 
 
 
104/1605 
(6.5) 
1501/1605 
 
 
104/1603 
(6.5) 
1499/1603 
 
 
7/177 (4.0) 
170/177 
 
 
3/174 
(1.7) 
171/174 
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(93.5) (93.5) (96.0) (98.3) 
 
Table 2-2   Table of baseline characteristics of whole AZURE 
populations and questionnaire responders 
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  Control 
(n=176) 
 
 
 
 
 
 
 
(  
Zol 
(n=186)  
Mean age, years (range)  57 (36-79) 57 (38-79) 
Dentures wearers (%)  35 (20)  39 (21)  
Missing teeth (%)  124 (70)  136 (73)  
Teeth or gums in need of attention 
(%) 
 40 (23)  38 (20)  
Number of tooth extractions (%) None  115 (65)  145 (78)  
 One  33 (19)  25 (13)  
 2-5  22 (13)  13 (7)  
 >5  5 (3)  1 (1)  
 Missing data  1 (1)  2 (1)  
Number of dental implants (%) None  165 (94)  170 (91)  
 One  6 (3)  6 (3)  
 2-5  2 (1)  4 (2)  
 >5  1 (1)  3 (2)  
 Missing data  2 (1)  3 (2)  
Number of surgical dental 
procedures (%) 
 
None  
 
136 (77)  
 
142 (76)  
 
 One  17 (10)  24 (13)  
 2-5  19 (11)  12 (6)  
 >5  2 (1)  4 (3)  
 Missing data  2 (1)  4 (2)  
Number of dental visits (%) ≥ 2 visits per year  123 (70)  137 (74)  
 Once per year  30 (17)  27 (15)  
 < Once per year  8 (5)  10 (5)  
 Not in 5 years  14 (8)  11 (6)  
 Missing  1 (1)  1(1)  
Table 2-3   Dental characteristics of questionnaire responders 
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2.4.2.2 Last 1 month 
Seven participants were excluded from this analysis due to more than 2 
missing responses (control, n=4; ZOL, n=3). Mean severity scores did not 
significantly differ according to arm. The mean score in the control group 
was 4.86 (SD, 8.581; 95% CI, 3.58 to 6.14) compared with 4.21 (SD, 7.361; 
95% CI, 3.14 to 5.28) in the ZOL arm (p = .440). Dentures worn (p<.001), 
teeth or gums in need of attention (p<.001) and number of tooth extractions 
(p<.001) significantly increased OHIP-14 scores. Severity of individual 
domain scores did not differ significantly by arm of study (table 2-4). 
The prevalence scores for the control and ZOL groups were 16.3% and 
13.7% respectively (difference, 2.6%; 95% CI -4.8% to 10%). The frequency 
of experienced impacts across the domains is shown in figure 2-3. Pain was 
the most commonly recorded impact. 
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Figure 2-3   Prevalence of impacts at the three highest levels by arm for 
last 1 month
0 10 20 30 40 50 60 70
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Fu
n
ct
io
n
al
lim
it
at
io
n
P
h
ys
ic
al
p
ai
n
P
sy
ch
o
lo
gi
ca
l
d
is
co
m
fo
r
t
P
h
ys
ic
al
d
is
ab
ili
ty
P
sy
ch
o
lo
gi
ca
l
d
is
ab
ili
ty
So
ci
al
d
is
ab
ili
ty
H
an
d
ic
ap
% of respondents 
D
O
M
A
IN
S 
O
F 
IM
P
A
C
T
 
Occasionally
Fairly often
Very Often
- 69 - 
 
Last 1 month Since randomisation 
Domain 
Control 
Group 
Zoledronate 
Group 
Mean difference 
(95% CI) 
P Control 
Group 
Zoledronate 
Group 
Mean difference 
(95% CI) 
P 
Functional limitation 
0.295 0.217 0.078(-0.04-0.199) 0.481 0.386 0.259 0.127(-.001-.254) 0.177 
Physical pain 0.806 0.748 0.058(-.132-.249) 0.637 0.857 0.784 0.073(-.117-.263) 0.641 
Psychological discomfort 
0.578 0.439 0.139(-.057-.335) 0.370 0.547 0.400 0.147(-.035-.237) 0.323 
Physical disability 
0.297 0.249 0.048(-.082-.178) 0.812 0.740 0.594 0.099(-.039-.237) 0.732 
Psychological disability 
0.419 0.364 0.056(-.110-.221) 0.945 0.509 0.383 0.126(-.043-.294) 0.512 
Social disability 0.214 0.218 -0.004(-.126-.118) 0.145 0.298 0.252 -0.047(-.082-.175) 0.316 
Handicap 0.259 0.187 0.072(-.045-.188) 0.891 0.312 0.209 0.103(-.019-.225) 0.565 
Table 2-4   Individual domain scores from OHIP-14 by arm of study for both time periods 
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2.4.2.3 Time since randomisation 
Four participants were excluded from this analysis due to more than 2 
missing responses (control, n=2; ZOL, n=2). Mean severity scores did not 
significantly differ according to arm. The mean score in the control group 
was 6.46 (SD, 9.624; 95% CI, 5.03 to 7.89) compared with 5.06 (SD, 7.292; 
95% CI, 4.01 to 6.11) in the ZOL arm (p = .119). Dentures worn (p=.002), 
teeth or gums in need of attention (p<.001) and number of tooth extractions 
(p<.001) significantly increased OHIP-14 scores. Severity of individual 
domain scores did not differ significantly by arm or study (table 2-4). 
When occurrence of a dental AE was included in the statistical model, this 
was also shown to be a significant independent prognostic factor (p<0.001). 
Treatment with ZOL remained a non-significant factor when dental AEs were 
added to the model (p=.109).  
The prevalence scores for the control and ZOL groups were 15.5% and 
12.9% respectively (difference, 2.6%; 95% CI -4.7% to 9.9%). The frequency 
of experienced impacts across the domains is shown in figure 2-4. Pain was 
the most commonly recorded impact. 
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Figure 2-4   Prevalence of impacts at the three highest frequency levels 
by arm for time since randomisation  
 
2.4.2.4 Dental AEs among responders 
There were 55 dental AEs reported among 45 patients. 84% of these AEs 
were reported in the ZOL arm. There were only 2 CTC grade 3 events, an 
episode of jaw pain and a report of loose teeth. There were two grade 4 
events. The mean OHIP-14 scores for patients who did experience a dental 
AE versus those who did not were 10.10 (95% CI 6.22 to 13.98) and 4.98 
(95% CI, 4.15 to 5.81) respectively, since randomisation. For scores within 
0 10 20 30 40 50 60 70
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Control
ZA
Fu
n
ct
io
n
al
lim
it
at
io
n
P
h
ys
ic
al
p
ai
n
P
sy
ch
o
lo
gi
c
al
d
is
co
m
fo
rt
P
h
ys
ic
al
d
is
ab
ili
ty
P
sy
ch
o
lo
gi
c
al
 d
is
ab
ili
ty
So
ci
al
d
is
ab
ili
ty
H
an
d
ic
ap
% of respondents 
D
O
M
A
IN
S 
O
F 
IM
P
A
C
T 
Occasionally
Fairly often
Very Often
- 72 - 
the last 1 month, the mean OHIP-14 scores for patients who did experience 
a dental AE versus those who did not were 7.95 (95% CI, 4.42 to 11.48) and 
4.68 (95% CI, 3.84 to 5.52) respectively. 
Of the patients invited to participate in the OH-QoL study, 3 had a reported 
case of suspected ONJ. Of these 3, one did not return the questionnaire and 
one did not meet the ONJ definition criteria. The remaining patient with a 
confirmed case of ONJ had OHIP-14 severity scores for the last 1 month 
and time since randomisation respectively of 32 and 28. The patient with 
suspected ONJ that did not meet the criteria also had higher than mean 
scores at both time points (scores for last 1 month and time since 
randomisation 18 and 19 respectively). 
 
2.5 Discussion 
ONJ is known to occur in both the benign and metastatic settings following 
treatment with either bisphosphonates or the RANK ligand inhibitor 
denosumab. Regarding intravenous bisphosphonates in the malignant 
setting, the cumulative incidence has been reported between 0.8% and 12%, 
though extreme value only reported in multiple myeloma106. As more data 
has emerged, key risk factors for the condition have been identified, 
including potency of bisphosphonate, duration of treatment with the drug and 
dentoalveolar surgery. ZOL is the most potent bisphosphonate used in 
clinical practice and therefore the majority of cases of ONJ occur in patients 
who have received this treatment. The AAOMS position paper reports that 
patients receiving intravenous bisphosphonate treatment are at a 2.7 – 4.2-
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fold increased risk of developing ONJ, that risk increases with longer 
duration and the patients who undergo dentoalveolar surgery are at least 7 
times more likely to develop ONJ. Our study is in agreement with this, the 
majority of our cases developing on the background of dental extractions 
and after at least 13 intravenous ZOL administrations. It is reassuring that 
since the time of this analysis there have only been 4 further cases of ONJ 
confirmed within the AZURE cohort195. 
During the conduct of the AZURE clinical trial, guidance emerged regarding 
diagnosis, treatment and prevention of ONJ that was distributed to 
investigators in addition to dental hygiene advice sent to all patients. There 
is now increasing evidence that implementing preventative measures can 
reduce the occurrence of ONJ and these measures are strongly 
recommended to all patients receiving intravenous bisphosphonate 
treatment124, 125, 196, 197. Such measures involve thorough oral investigation 
before starting intravenous bisphosphonate treatment, removal of any 
unsalvageable teeth, completion of any invasive dental procedures before 
commencing i.v. BP treatment and maintaining optimal periodontal health106. 
In the metastatic setting, the cumulative incidence of ONJ has been reported 
as 3.0% (95% CI 0 – 5.8%) with ZOL198. The cumulative incidence of ONJ in 
our study is lower than this at 2.1% however it is higher than that reported in 
other adjuvant settings. This is likely due to the less intense schedule of ZOL 
in these studies. The ZO-FAST and Z-FAST studies administered ZOL 4mg 
i.v. 6 monthly for 5 years (total 10 administrations) and report 3 and 0 
confirmed cases respectively133, 199. The ABSCG-12 study administered ZOL 
4mg i.v. 6 monthly for 3 years at no report no confirmed cases of ONJ200. 
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We also report an apparent increase in reported dental AEs in the ZOL arm. 
However, as this study was notblinded, it is likely that there has been 
differential reporting of dental-specific AEs, with a tendency to under-report 
oral issues in the control arm. Additionally, some of these patients with a 
reported dental AE may be considered stage 0 ONJ following the 
amendment to the staging system in 2009 by AAOMS with nonspecific 
symptoms that may result from bisphosphonate exposure and an unknown 
risk for advancing to higher disease stage. While the AAOMS does 
acknowledge that ONJ adversely affects quality of life, it is unknown whether 
the wider population of patients receiving potent i.v. bisphosphonates also 
experience negative impacts on their OH-QoL. 
Our study remains the only published report of OH-QoL investigated in early 
breast cancer183. The OHIP-14 has been used to assess OH-QoL in a 
retrospective cohort of 34 cancer patients with confirmed ONJ, before and 
after the diagnosis of ONJ. They show that ONJ significantly increases 
severity scores from a mean of 3.56 to 16.53 however there is no 
comparison with patients who did not go on to develop ONJ. In addition to 
the general tool EORTC-C30 survey, Kyrgidis et al used the EORTC QLQ 
Head and Neck 35 to investigate oral-specific impacts on quality of life 
related to ONJ193. This module includes 35 items covering pain, swallowing, 
taste, smell, speech, social eating, social contact, sexuality, teeth problems, 
trismus, dry mouth, sticky saliva, cough and feeling ill. The authors conclude 
that use of the QLQ-HN35 module might be applicable to patients with any 
type of metastatic cancer who develop ONJ. However, there are many 
questions included in this survey that are inappropriate for early cancer 
patients who have received curative treatment and also may be considered 
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inappropriate for patients with ONJ for example, questions regarding feeding 
and cough. Furthermore, the questions regarding appearance and sexuality 
may put patients off from completing the questionnaire, as seen by the 
authors.  
Our data are encouraging and reassuring to clinicians and patients, showing 
that ZOL does not seem to significantly affect OH-QoL. The mean scores we 
report are similar to those from both a general healthy adult population in the 
UK and the wider global community189, 201. The relationship between 
reporting of a dental AE during the study and worse OH-QoL scores strongly 
suggests that the OHIP-14 is sensitive to oral health events in patients with 
early breast cancer. Given the widespread use of ZOL and the recent results 
in the adjuvant setting indicating that bisphosphonates may improve DFS 
and OS, the knowledge that there seems to be no demonstrable adverse 
impact on OH-QoL is reassuring encouraging. 
A limitation of this study is that it evaluated OH-QoL at a single timepoint at 
completion of 5 years on study and relied on a retrospective evaluation by 
the patient of QoL at only 2 time frames. Ideally, a prospective longitudinal 
study would have been conducted, however the potential link between BP 
use and ONJ was not known when the study was designed and initially 
commenced accrual. It is acknowledged that there are other methods 
recognised for investigating quality of life amongst patients, such as 
conducting face-to-face or telephone interviews, however, this would have 
been more time consuming and may have prohibited some from 
participating. 
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It is now accepted that the non-bisphosphonate antiresorptive agent 
denosumab is also associated with the development of ONJ and at a 
frequency at least as high as seen with ZOL in the metastatic setting, 
providing further need for additional research. It seems unlikely that a bone-
targeted agent will become available in the near future that is not associated 
with the development of ONJ. Whilst our study has provided important new 
information on both ONJ and oral health quality of life in patient receiving 
ZOL, it is desirable to understand the potential genetic, oral health and 
treatment risk factors, incidence and resolution of this uncommon problem 
somewhat better than we do at the present time. The adjuvant phase III 
clinical trial of denosumab as adjuvant treatment for women with early stage 
breast cancer (D-CARE; NCT01077154) has similar eligibility to AZURE, 
whereas the Austrian Breast and Colorectal Cancer Group-18 
(NCT00556374) trial is evaluating an every 6-month osteoporosis dosing 
schedule of denosumab. The placebo-controlled, double-blind study design 
of these studies will provide additional and supplementary information on 
dental safety and ONJ incidence.   
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3 Serum biomarkers of bone metabolism as prognostic 
and predictive factors  
3.1 Background 
The work considered in this chapter has been published in the Journal of the 
National Cancer Institute202. I undertook the laboratory work required for the 
manual assay 1CTP in over 800 samples, in addition to running some of the 
automated assays. Furthermore, I was a principal member of the group 
analysing the data, participated in numerous discussions on the statistical 
analysis and I am joint first author on the published manuscript to 
acknowledge my significant contribution. 
As outlined in the Introduction, markers of bone metabolism can be easily 
measured in serum or urine and can give an indication of the state of bone 
health and turnover, but interpretation must take into account diurnal 
variation, seasonal changes and diet. Due to the known interactions 
between the bone microenvironment and breast cancer cells, we propose 
that markers of bone metabolism may provide useful prognostic information 
and additionally identify patients who may benefit from adjuvant 
bisphosphonates. As a planned translational component of AZURE, serum 
samples were collected from consenting participants to investigate the 
underlying mechanisms and status of the bone microenvironment, as 
reflected in the markers. Furthermore, we planned to investigate whether the 
markers are able to identify high-risk patients and if manipulation of the bone 
- 78 - 
microenvironment with bone-targeting agents in the adjuvant setting reduces 
the risk of recurrence. 
Four serum markers were chosen for investigation: P1NP, CTX, 1CTP and 
total 25-hydroxyvitamin D (25-OH vitamin D). All four are markers that can 
be reliably tested in the laboratory and are well-validated. The 4 markers 
represent different aspects of bone metabolism. P1NP is a marker of bone 
formation while CTX is a marker of bone resorption. 1CTP is an additional 
marker of bone resorption however it is released by the action of matrix 
metalloproteinases (MMPs; proteolytic enzymes involved in the degradation 
of matrix) and is not affected by menopausal status. Finally, vitamin D is 
integral to bone metabolism; its levels are closely regulated by calcium and 
phosphate levels and parathyroid hormone, the latter also having a role in 
activating osteoblasts, stimulating the transformation of pre-osteoclasts into 
mature osteoclasts203. It is now widely accepted as playing a role in many 
cellular mechanisms related to cancer including differentiation, proliferation, 
apoptosis and angiogenesis. 
Whilst it is known, to varying degrees, that these markers can display 
prognostic information, the evidence has never been robust enough to guide 
clinical practice. We had a unique opportunity within the AZURE clinical trial 
to significantly improve upon this by correlating our laboratory findings with 
the database collected at Leeds CTRU. Additionally, in light of the published 
efficacy data for adjuvant zoledronic acid, we were able to investigate 
whether it is possible to identify patients at baseline who may benefit from 
the treatment, other than on the basis of menopausal status. 
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3.2 Hypotheses tested 
1. Markers of bone metabolism (P1NP, CTX, 1CTP, vitamin D) can 
identify patients at risk of developing bone metastasis from early 
breast cancer. 
2. Markers of bone metabolism (P1NP, CTX, 1CTP, vitamin D) can 
identify patients with early breast cancer who will develop (any site) 
disease recurrence. 
3. Patients who have elevated bone turnover at baseline (determined by 
levels of P1NP, CTX and 1CTP) benefit from adjuvant treatment with 
zoledronic acid, compared with controls, in terms of skeletal 
recurrence. 
4. Patients who have elevated bone turnover at baseline (determined by 
levels of P1NP, CTX and 1CTP) benefit from adjuvant treatment with 
zoledronic acid, compared with controls, in terms of (any site) disease 
recurrence. 
5. Levels of vitamin D cannot predict which patients may benefit from 
adjuvant treatment with zoledronic acid. 
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3.3 Methods 
3.3.1 Patients and data collection 
The AZURE trial design and methods have been published elsewhere204. In 
brief, women with histologically confirmed breast cancer and either lymph 
node metastasis or T3/T4 primary tumour were eligible to participate. 
Following written, informed consent, participants were randomised to either 
standard (neo)adjuvant therapy (control arm) or standard (neo)adjuvant 
therapy plus intravenous zoledronic acid (ZOL) 4mg (treatment arm) for a 
total treatment duration of 5 years (figure 1-4). Additionally, calcium and 
vitamin D supplementation was recommended for all trial participants for the 
first 6 months on study (until visit 6) to be continued thereafter at the 
discretion of the treating clinician.  
In addition to the main trial, participants at UK centres were invited to take 
part in the translational studies by giving additional consent for the collection 
of serum samples at study entry. No serial samples were taken. Samples 
collected at UK centres were stored at -20°C or -80°C depending on local 
facilities. Following regular transfer to Sheffield, samples were kept at -80°C 
until central batch analysis. 
 
3.3.2 Laboratory methods 
All markers were measured according to strict SOPs in a fully accredited 
central laboratory (Metabolic Bone Unit, University of Sheffield). 
Procollagen type I N-telopeptide propeptide (PINP), cross-linked c-
telopeptide of type I collagen (CTX) and 25-hydroxyvitamin D (25-OH 
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vitamin D) were measured using Cobas e411 automated immunoassays 
(Roche Diagnostic, Germany). Pyridinoline cross-linked c-terminal 
telopeptide of type I collagen (1CTP) was measured by manual 
enzymeimmunoassay (Orion Diagnostica UniQ ICTP EIA, Finland). 
The P1NP assay works on the sandwich principle, with an initial incubation 
of 20µl of sample with a biotinylated monoclonal mouse antibody specific for 
P1NP. This is followed by a second incubation of streptavidin labelled 
microparticles with a mouse monoclonal P1NP-specific antibody labelled 
with a ruthenium complex. The microparticles within the reaction mixture are 
captured magnetically onto the surface of the electrode, through which a 
voltage is applied, inducing a chemiluminescent emission which is captured 
by a photomultiplier. Results are determined via a calibration curve. 
The P1NP assay has a lower detection limit of < 5ng/ml and values were 
categorised as “high” if greater than or equal to 70ng/ml base based on 
previous reports of a possible predictive role of PINP in the development of 
bone metastases13 and advice from Roche Diagnostics. Results lower than 
70 ng/ml were categorised as “normal”.  
The principle of the assay for CTX is the same as that for P1NP, except that 
the mouse monoclonal antibodies used are specific for CTX. The CTX assay 
has a measuring range of 0.010 – 6.00ng/ml. The upper limit of normal for 
premenopausal women (0.299 ng/ml) was used to categorise results has 
either “high” (≥0.299) or “normal” (<0.299). An additional analysis with a 
higher threshold (high >0.556) was carried out to allow a closer comparison 
with the earlier study by Lipton et al175. 
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The total 25-OH vitamin D assay works on the competition principle. There 
are 3 incubations. The first is a pre-treatment dithiotheitol and sodium 
hydroxide to release bound 25-hydroxyvitamin D from the vitamin D binding 
protein. The pre-treatment sample is then incubated with ruthenium labelled 
vitamin D binding protein, forming a complex. Finally, after the addition of 
streptavidin-coated microparticles and 25-hydroxyvitamin D labelled with 
biotin, the free sites of the ruthenium labelled vitamin D binding protein 
become occupied and form a complex. The microparticles within the reaction 
mixture are captured magnetically onto the surface of the electrode, through 
which a voltage is applied, inducing a chemiluminescent emission which is 
captured by a photomultiplier. Results are determined via a calibration curve. 
 The vitamin D assay has a measuring range of 3.0-70.0 ng/ml and values 
were categorised as either “sufficient” or “insufficient”. A level of ≥ 30 ng/ml 
was chosen to classify participants as “sufficient” based on expert 
consensus that this is the desirable concentration required for good general 
health205, 206.  
1CTP was conducted as a manual assay which is based on the competitive 
immunoassay principle according to the following procedure. 
1. All reagents, controls and patient samples were brought up to room 
temperature at least 30 minutes before use. 
2. 50µl of calibrator, control and patient sample were pipetted in duplicate 
into appropriate microtitre wells coated with goat anti-rabbit antibodies. 2 
wells were reserved for the substrate blank. 
3. 50µl of peroxidise labelled 1CTP were pipetted into all wells except 
blanks 
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4. 50µl of rabbit antiserum were pipetted into all wells except blanks, within 
3 minutes. 
5. The plate was incubated on a plate shaker at room temperature for 2 
hours using a shaking speed of 600 rpm. 
6. All wells were washed 4 times with the provided wash solution. All 
remaining moisture was removed by tapping firmly against absorbent 
paper. 
7. 100µl of 3,3,5,5’-tetramethylbenzidine was pipetted into all wells.  
8. The plate was incubated on a plate shaker at room temperature for 30 
minutes.  
9. The enzyme reaction was stopped by adding 100µl of 0.5M H2SO4 into 
all wells. The plate was placed back on the plate shaker for a further 30 
seconds to mix the reagents. 
10. Absorbances of all wells were read at 450 nm on a plate reader within 10 
minutes.  
 
The assay has a lower detection limit of 0.3 µg/l. Upper limit or normal was 
4.2 ng/ml.   
The inter-assay coefficient of variance (CV) will be calculated for each 
assay.  
All markers were also examined as continuous variables. 
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3.3.3 Statistical analysis 
All analyses were performed using SAS version 9.2 or 9.4. 
Statistical analysis was performed on the final analysis datalock for AZURE, 
after a median of 84.2 months follow up and 966 disease-free survival 
events in the 3359 AZURE participants. All analyses were performed on the 
intention-to-treat population and included 872 UK patients who consented to 
the collection of samples. Hypothesis testing was performed at the two-sided 
5% level.  Analyses were performed for all participants combined and 
according to menopausal status. 
 
Cumulative incidence function (CIF) curves were used to investigate time to 
bone as first recurrence and distant recurrence, to take into account 
competing risks. Cox’s proportional hazards model was used to assess the 
relationships between the bone biomarkers and prognosis and treatment 
effect with zoledronic acid. Bone marker data were analysed both as 
continuous variables (log transformed) and as categorical variables, using 
the pre-specified high versus normal cut-points above for both prognostic 
and predictive relationships. 
 
Analyses were adjusted for factors which were found to have a statistically 
significant prognostic effect on the relevant outcome in the main AZURE 
analyses. For bone as first recurrence analysis was adjusted for lymph node 
involvement, tumour stage and treatment allocation. For distant recurrence, 
analysis was adjusted for lymph node involvement, tumour stage and ER 
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status. For IDFS and IDFS component analyses analysis was adjusted for 
lymph node involvement, tumour stage, ER status and neo-adjuvant therapy. 
Analyses are also adjusted for treatment allocation when assessing the 
interaction of the markers with treatment (i.e. the predictive analyses), where 
the interaction term is used to test for heterogeneity between the different 
markers levels. 
 
Prognostic analyses of bone recurrence at any time (whether or not bone 
was the first site of recurrence), time to first recurrence being in bone (either 
in bone-only or with synchronous distant metastasis) and time to first distant 
recurrence were carried out. Predictive analyses of IDFS and its 
components for vitamin D, P1NP, CTX and 1CTP, overall and by 
menopausal status, were all pre-specified prior to the analyses taking place. 
Exploratory analyses with the composite P1NP/CTX biomarker were carried 
out, in terms of both markers high versus no both markers high. 
 
Additional analyses of the vitamin D data were undertaken using normalised 
values. Vitamin D values were normalised to account for the seasonal 
variation in baseline vitamin D. The monthly means were calculated, and a 
log (base 10) was used for smoothing. These, along with the overall (log) 
mean, were used to normalise each patient’s baseline vitamin D value by 
dividing their log vitamin D value by the monthly (log) mean and multiplying 
by the overall (log) mean, before raising 10 to the power of this log 
normalised result, to calculate their normalised vitamin D value.  
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3.4 Results 
3.4.1 Baseline characteristics 
Baseline samples of stored serum from 872 patients were available for 
translational studies (441 control arm, 431 treatment arm). The median 
follow up for these patients was 84.2 months (range, 0-107.6 months; IQR, 
71.7-92.1 months). Baseline characteristics are displayed in table 3.1.  Mean 
age at baseline was 51.2 years (range 25-79) and 51.6 years (range 28-79) 
in the control and treatment arms, respectively. The baseline characteristics 
of the serum biomarker population are compared with those of the whole 
main AZURE population in table 3-2 showing that they have similar 
demographics. 
 
 
 
Control arm Treatment arm 
Number Percent Number Percent 
Tumour stage 
139 31.5 146 33.9 T1 
T2 227 51.5 200 46.4 
T3 59 13.4 72 16.7 
T4 16 3.6 13 3.0 
Neo-adjuvant therapy 
24 5.4 28 6.5 Yes 
No 417 94.6 403 93.5 
Systemic therapy 
20 4.5 13 3.0 
Endocrine therapy 
alone 
Chemotherapy alone 95 21.5 95 22.0 
Both 326 73.9 323 74.9 
Menopausal status     
Pre-menopausal 209 47.4 200 46.4 
≤5 years since 
menopause 63 14.3 60 13.9 
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Control arm Treatment arm 
Number Percent Number Percent 
>5 years since 
menopause 134 30.4 132 30.6 
Menstrual status 
unknown 35 7.9 39 9.0 
ER status      
ER positive 338 76.6 338 78.4 
ER negative 101 22.9 91 21.1 
ER unknown 2 0.5 2 0.5 
PR status      
Positive 181 41.0 180 41.8 
Negative 114 25.9 91 21.1 
Unknown 146 33.1 158 36.7 
Missing 0 0.0 2 0.5 
HER2 status      
Positive 59 13.4 49 11.4 
Negative 154 34.9 164 38.1 
Unknown 16 3.6 14 3.2 
Not measured 211 47.8 201 46.6 
Missing data 1 0.2 3 0.7 
Lymph node 
involvement      
0 7 1.6 9 2.1 
One - three nodes 
involved 277 62.8 257 59.6 
≥ four nodes involved 157 35.6 163 37.8 
Unknown involvement 0 0.0 2 0.5 
Table 3-1   Baseline characteristics of 872 patients who had serum 
available for markers analysis 
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 Biomarker population, n 
(%) 
Main AZURE population, n 
(%) 
Lymph node status 
0  
1-3 
≥ 4 
Unknown 
 
15 (1.7) 
534 (61.2) 
320 (36.7) 
3 (0.3) 
 
62 (1.8) 
2075 (61.8) 
1211 (36.1) 
11 (0.3) 
T stage 
T1 
T2 
T3 
T4 
 
285 (32.7) 
427 (49.0) 
131 (15.0) 
29 (3.3) 
 
1065 (31.7) 
1717 (51.1) 
456 (13.6) 
117 (3.5) 
ER status 
Positive 
Negative 
Unknown 
 
676 (77.5) 
192 (22.0) 
4 (0.5) 
 
2634 (78.4) 
705 (21.0) 
20 (0.6) 
Menopausal status 
Pre-menopausal 
≤ 5 years since menopause 
> 5 years since menopause 
Unknown 
 
409 (46.9) 
123 (14.1) 
266 (30.5) 
74 (8.5) 
 
1504 (44.8) 
490 (14.6) 
1041 (31.0) 
324 (9.6) 
Table 3-2  Table comparing the baseline characteristics of the serum 
biomarker population with the main AZURE population. 
 
Baseline data for the three biomarkers (also broken down into menopausal 
status), revealed that the proportion of patients in each category who fall 
above the normal ranges for P1NP, CTX and 1-CTP for the whole population 
were 27.3%, 30.0% and 50.5% respectively (Table 2), confirming that the 
data were appropriate to test the relationship between accelerated baseline 
bone turnover and subsequent distant recurrence events. As expected for 
the transition through menopause, the median values for each of the three 
bone turnover biomarkers showed a stepwise increase from pre-menopausal 
through peri-menopausal to > 5 years post-menopausal women. 
 
An analysis was performed to determine whether the outcomes of the subset 
of AZURE patients within the biomarker study (872 patients) are 
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representative of the whole AZURE population as shown in Figure 3-1 
(analysis carried out by Helen Marshall and Walter Gregory at Leeds 
CTRU). For all analyses, the hazard ratios (HR) in the biomarker population 
are in the same direction and of similar magnitude to those seen in the main 
AZURE analyses.  Although the confidence intervals are wider in the 
biomarker population, as expected due to the smaller number of patients 
compared to the whole AZURE population, the disease outcomes of the 
biomarker subset of patients are similar to the randomised study groups as a 
whole. 
 
 
 
Figure 3-1   Forest plot of Invasive Disease Free Survival (IDFS) 
treatment hazard ratios and 95% confidence intervals (CIs) for all 
patients in the AZURE study (black) and patients in the biomarker 
population (blue). 
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Baseline results of the bone turnover markers (P1NP, CTX and 1CTP) are 
shown below in table 3-3.  
 
 
P1NP values were not normally distributed, therefore they were log 
transformed using base 10 to approximate a normal distribution (figures 3-1 
and 3-2).  
 
Figure 3-2 Distribution of P1NP values 
 
 
Marker Inter-assay CV (%) Mean SD IQR 
P1NP 4.1 59.1 26.92 41.2-72.7 
CTX 4.0 .259 .153 .154-.324 
1CTP 5.7 4.39 1.55 3.26-5.15 
Table 3-3   Baseline data from bone turnover marker assays 
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Figure 3-3 P1NP log transformed (using base 10) to approximate a 
normal distribution 
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Menopausal status 
Pre-menopausal 
≤ 5 years since 
menopause 
> 5 years since 
menopause 
Menstrual status 
unknown 
n % n % n % N % 
P1NP         
Normal 334 81.7 84 68.3 160 60.2 51 68.9 
High 75 18.3 37 30.1 103 38.7 23 31.1 
Missing 0 0.0 2 1.6 3 1.1 0 0.0 
CTX         
Normal 337 82.4 74 60.2 140 52.6 50 67.6 
High 71 17.4 46 37.4 122 45.9 23 31.1 
Missing 1 0.2 3 2.4 4 1.5 1 1.4 
1CTP         
Normal 226 55.3 57 46.3 101 38.0 37 50.0 
High 182 44.5 61 49.6 164 61.7 33 44.6 
Missing 1 0.2 5 4.1 1 0.4 4 5.4 
Vitamin D         
<=30 361 88.3 103 83.7 236 88.7 66 89.2 
>30 43 10.5 14 11.4 26 9.8 7 9.5 
Missing 5 1.2 6 4.9 4 1.5 1 1.4 
Table 3-4  Bone turnover markers by menopausal status (n, number). 
 
CTX and 1CTP values were similarly not normally distributed, therefore they 
were log transformed using base e to approximate a normal distribution 
(figures 3-4 to 3-7). 
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Figure 3-4   Distribution of CTX values 
 
 
Figure 3-5   CTX log transformed (base e) to approximate normal 
distribution 
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Figure 3-6   Distribution of 1CTP values 
 
 
 
Figure 3-7 1CTP log transformed (using base e) to approximate a 
normal distribution 
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3.4.2 Bone recurrence at any time 
When analysed as a continuous log transformed variable (adjusted for 
factors previously mentioned), all 3 bone turnover markers were associated 
with a statistically significant increased risk for development of bone 
metastasis (P1NP: p=0.006; CTX: p=0.009; 1-CTP: p=0.008; figure 3-8). 
When analysed as a categorical variable, both P1NP >70ng/ml (p= 0.03) 
and CTX >0.299 (p=0.03) were associated with statistically significant 
increased risk for development on bone metastasis at any time (table 3-5). 
This was not the case for CTX>0.566 (p=0.12) or 1CTP (p=0.010).  
 
Figure 3-8 Hazard ratios and 95% confidence intervals (CI) for adjusted 
continuous analyses of log transformed data for baseline PINP, 
CTX and 1-CTP and disease outcomes. 
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3.4.3 First recurrence in bone 
P1NP (p=0.03) and 1-CTP (p=0.045) were statistically significantly 
prognostic for first recurrence in bone in the adjusted continuous analyses 
(figure 3-8). However, the corresponding analyses for CTX showed that, 
although the HR values suggested increased risk, the results did not reach 
statistical significance. In adjusted categorical analyses, although the HRs 
for each marker were similar to bone recurrence at any time, the 95% CIs 
were wide and no statistically significant relationships between higher 
marker values and first disease recurrence in bone were seen. The number 
of bone-only first recurrence events was too small to justify separate 
analysis of this potential endpoint of interest. 
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Marker Bone recurrence 
at any time 
HR (95% CI; p-
value) 
First recurrence 
in bone 
HR (95% CI) 
First distant 
recurrence 
HR (95% CI) 
P1NP  
High vs. normal 
 
1.61 (1.07-2.42; 
p=0.03) 
 
1.58 (1.00-2.50; 
p=0.06) 
 
0.99 (0.72-1.37; 
p=0.96) 
CTX 
>0.299 vs. ≤0.299 
 
>0.556 vs. ≤0.556 
 
1.55 (1.05-2.31;  
p=0.03) 
2.17 (0.94-5.01; 
p=0.10) 
 
 
1.27 (0.80-2.00;  
p=0.32) 
1.95 (0.90-4.21; 
p=0.12) 
 
1.26 (0.93-1.71;  
p=0.13) 
0.94 (0.47-1.86; 
p=0.85) 
1CTP 
High vs. normal 
 
1.39 (0.94-2.05; 
p=0.10) 
 
1.30 (0.84-2.02; 
p=0.24) 
 
1.19 (0.89-1.59; 
p=0.25) 
Table 3-5  Results from categorical analysis of bone markers for the 3 
end-points 
 
 
3.4.4 First distant recurrence 
None of the 3 bone markers demonstrated statistical significance as a 
prognostic biomarker for distant recurrence, either as a categorical or 
continuous variable in an adjusted analysis (figure 3-8). 
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3.4.5 Composite P1NP and CTX biomarker analysis 
Analyses were performed to assess risks of recurrence for patients where 
both P1NP and CTX were high (using the 0.299 ng/ml cutpoint for CTX) 
compared with all other patients. The adjusted analyses, along with the 
numbers of recurrence events for each endpoint for this composite 
categorical biomarker are displayed in table 3-6. No statistically significant 
relationships were identified between the composite marker and subsequent 
recurrence, although there was a borderline significant increased risk for 
bone recurrence at any time in the patients with elevation of both biomarkers 
(HR = 1.60, 95%CI 0.99, 2.48, p = 0.06). 
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Analysis 
P1NP, CTX Adjusted analysis 
Both High 
Events/Censored 
(%) 
Not Both High 
Events/Censored 
(%) 
 
HR 
 
95%CI 
p-
value* 
Bone 
recurrence 
at any time 
 
24/118 (16.9) 
 
80/641 (11.1) 
 
1.60 
 
0.99   
2.48 
 
0.06 
First 
recurrence 
being in 
bone 
 
18/124 (12.7) 
 
64/657 (8.9) 
 
1.50 
 
0.89   
2.54 
 
0.14 
First distant 
recurrence 
(at any site) 
 
34/108 (23.9) 
 
154/567 (21.4) 
 
1.00 
 
0.68   
1.45 
 
0.99 
First 
recurrence 
being in 
bone only 
 
11/131 (7.7) 
 
47/674 (6.5) 
 
1.26 
 
0.65   
2.44 
 
0.50 
Table 3-6  Adjusted prognostic categorical analyses according to a 
composite P1NP-CTX marker for both P1NP and CTX high versus not 
both high. 
 
3.4.6 Sensitivity analyses assessing optimum cut-points 
Different cutpoints for categorical prognostic analysis of P1NP and bone 
metastasis at any time were explored. This analysis (figure 3-9) showed that 
the optimal cut-point for P1NP was approximately 64 nmol/ml, which we 
judged was sufficiently close to the pre-specified value of 70 nmol/ml, 
bearing in mind that the number of events was not sufficient to generate a 
smooth relationship. For 1-CTP and CTX, similar exploration yielded no 
clearly optimal cut-point or improvement to those pre-selected (data not 
shown). 
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Figure 3-9  Identification of optimum cut-points.  
χ² values from adjusted Cox proportional hazards model, analysing bone 
metastasis at any time by P1NP, with differing high vs. normal P1NP cut-
points. Optimum cut-point observed at 64ng/ml with a corresponding p-value 
of 0.003.  P1NP, N-terminal propeptide of type-1 collagen.  
 
3.4.7 Analyses for treatment effect – test for predictive 
biomarkers 
All 3 bone turnover markers and the composite P1NP/CTX marker were 
analysed to identify a potential predictive role in terms of benefit from 
zoledronic acid. In an adjusted analysis, no significant interaction with 
treatment allocation was identified for any of the three recurrence categories 
with any of the bone markers or the composite markers. This suggests that 
the bone markers do not predict for the benefits seen with zoledronate in 
postmenopausal women. 
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Although P1NP is higher in postmenopausal women and the benefits of 
zoledronate are largely restricted to this subset of patients, baseline P1NP 
did not predict benefit from zoledronate. For example, in cumulative 
incidence plots for effect of high P1NP on bone recurrence at any time or for 
bone as first recurrence (where we found a prognostic role for P1NP), there 
were no significant differences in outcome (HR 0.99 95%CI 0.52, 1.90, 
p=0.693; HR 0.84 95%CI 0.40, 1.75, p=0.680 respectively) between the 
zoledronate and control arms. Indeed, we found no significant interaction 
with treatment allocation for any of the four defined recurrence categories 
with any of the bone markers, or with the P1NP/CTX composite bone 
marker, suggesting that (data not shown).  
Corresponding continuous (log transformed) analyses for bone metastases 
at any time found no statistically significant interaction with treatment 
allocation for any of the markers analysed: P1NP p=0.74; CTX p=0.47; 1-
CTP p=0.31, confirming that these baseline markers are not predictive for 
the treatment benefits of zoledronate. 
 
3.4.8 Vitamin D analyses 
Inter-assay CV for this assay was 4.6%. Mean vitamin D was 18.2ng/ml (SD 
= 9.25; IQR, 11.1-23.7; range, <3 – 54.8ng/ml). Values below the limit of 
detection (<3ng/ml) were included in the analysis as 3ng/ml. 16 patients had 
a missing value and have been excluded from the analysis. Values were not 
normally distributed, therefore they were log transformed using base 10 to 
approximate a normal distribution (figures 3-10 and 3-11). In the control arm 
8.6% had sufficient levels of vitamin D compared with 12.1% in the treatment 
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arm. Levels of vitamin D did not vary by menopausal status (tables 3-4 and 
3-7).  
 
Figure 3-10 Distribution of vitamin D levels 
 
 
 
 
Figure 3-11 Vitamin D log transformed (base 10) to approximate normal 
distribution 
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Menopausal 
status 
Number of 
patients  
Mean SD IQR Range 
Pre-
menopausal 
404 18.03 9.35 10.89-23.12 <3-54.82 
≤5 years since 
menopause 
117 19.26 10.14 11.32-24.97 4.44-49.39 
> 5 years since 
menopause 
262 17.83 8.98 11.02-23.18 <3-49.28 
Status 
unknown 
73 18.70 8.10 12.85-23.66 7.52-42.43 
Table 3-7  Vitamin D by menopausal status (measurements in ng/ml) 
 
 
At visit 6 approximately 87% of patients in each arm were receiving calcium 
and vitamin D supplements. After this point, supplements were prescribed at 
the clinician’s discretion and fell to 40.1% in the control arm and 51.1% in 
the treatment arm by visit 19 (final study visit).  
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3.4.8.1 Bone recurrence at any time 
The numbers of events included in this analysis are shown in table 3-8. For 
time to bone recurrence at any time there is no significant difference 
between the sufficient and low vitamin D categories, however there is a 
trend towards lower risk in the sufficient group (HR 0.52, 95% CI 0.24 – 
1.12; p=0.066). 
 
3.4.8.2 First recurrence in bone 
When adjusted for factors outlined in the methods, patients with sufficient 
levels of vitamin D at baseline have a lower risk for bone as a first 
recurrence but this does not reach statistical significance (HR 0.51; 95% CI, 
0.20-1.26; p=0.107). The cumulative incidence function is seen in figure 3-
12. This does not vary when additionally analysed by menopausal status. 
When analysed as a continuous variable vitamin D is not a significant 
prognostic marker for bone as a first recurrence (p=0.5545).   
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Vitamin D 
Total Missing ≤30 >30 
n % n % n % N % 
Bone only recurrence as first 
event  
16 100.0 710 92.7 88 97.8 814 93.3 Censored 
Event 0 0.0 56 7.3 2 2.2 58 6.7 
Bone recurrence as first event         
Censored 15 93.8 690 90.1 85 94.4 790 90.6 
Event 1 6.3 76 9.9 5 5.6 82 9.4 
Bone recurrence at any time         
Censored 15 93.8 670 87.5 83 92.2 768 88.1 
Event 1 6.3 96 12.5 7 7.8 104 11.9 
Distant recurrence 
15 93.8 
  
74 82.2 684 78.4 Censored 595 77.7 
Event 1 6.3 171 22.3 16 17.8 188 21.6 
Total 16 100.0 766 100.0 90 100.0 872 100.0 
Table 3-8  Number of events included in the vitamin D analyses 
 
 
- 106 - 
 
Figure 3-12  Cumulative incidence function for time to bone as first 
recurrence by vitamin D 
 
 
3.4.8.3 First distant recurrence 
The numbers of events included in this analysis are shown in table 3-6. 
Patients with sufficient levels of vitamin D have significantly lower risk for 
distant recurrence compared with those with low levels (HR 0.60; 95% CI 
0.36 – 1.00; p=0.0378). See cumulative incidence function figure 3-16. When 
the analysis is performed additionally adjusting for menopausal status there 
remains a statistically significant difference (HR 0.6, 95% CI 0.36-1.10; 
p=0.042). When comparing different menopausal groups, the benefit is seen 
only amongst the non post-menopausal patients (see table 3-9).  
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Figure 3-13 Cumulative incidence function for time to distant 
recurrence by vitamin D 
 
 
 
 
Menopausal status Analysis 
Hazard 
ratio 
Lower 
limit of 
95% CI 
Upper 
limit of 
95% CI 
Menopausal status 
interaction 
Χ
2
 test 
statistic 
 (DF) p-value 
Post-menopausal 
>30 vs. ≤30 vitamin D  
(adjusted) 
1.141 0.516 2.523 
3.0717 
(1 DF) 
0.0797 
Non post-menopausal 
>30 vs. ≤30 vitamin D  
(adjusted) 
0.437 0.221 0.866 
Table 3-9 Distant recurrence by vitamin D and menopausal status 
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3.4.8.4 Vitamin D as a continuous variable 
Vitamin D as a continuous variable is not statistically significant as a 
prognostic marker for the development of bone as first recurrence (HR 0.99, 
95% CI 0.97-1.02; p=0.555) or distant recurrence (HR 0.99, 95% CI 0.98-
1.01; p=0.382).  
 
3.4.8.5 Vitamin D treatment interaction 
In terms of bone recurrence at any time and first recurrence in bone, there is 
a trend for increasing benefit from zoledronic acid in the sufficient vitamin D 
group however this is not statistically significant (table 3-10). 
 
 
 Vitamin D 
level 
HR 95% CI Treatment 
interaction p 
value. 
Bone recurrence 
at any time 
≤30 
>30 
0.985 
0.425 
0.657-1.477 
0.094-1.913 
 
0.287 
First recurrence 
in bone 
≤30 
>30 
0.823 
0.365 
0.521-1.301 
0.060-2.207 
 
0.386 
Table 3-10  Bone recurrence by randomised treatment arm – analysis 
of Zol vs. control by vitamin D category. 
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For distant recurrence, separate analyses were undertaken for non post-
menopausal patients and post-menopausal patient. Following treatment 
interaction analysis, HR for non-post-menopausal patients with sufficient 
vitamin D treated with zoledronic acid was 0.712 (0.190 – 2.673) compared 
with 1.159 (0.803 – 1.672) for those with low vitamin D (p value for 
interaction = 0.4906). HR for post-menopausal patients with sufficient 
vitamin D treated with zoledronic acid was 0.081 (0.010 – 0.688) compared 
with 1.008 (0.572 – 1.778) for those with low vitamin D (p value for 
interaction = 0.0065). 
 
For all components of the IDFS analysis, risk of recurrence is lower for 
patients with sufficient vitamin D levels compared with deficient levels (see 
table 3-11). 
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Component Vitamin D  
Hazard ratios Treatment interaction 
Hazard 
ratio 
Lower 
limit of 
95% CI 
Upper 
limit of 
95% CI 
Χ
2
 test 
statistic  
(1 DF) p-value 
Skeletal distant 
recurrence 
≤30 0.821 0.517 1.304 
0.8970 0.3436 
>30  0.339 0.056 2.050 
Non-skeletal distant 
recurrence 
≤30 1.386 0.914 2.103 
2.2957 0.1297 
>30  0.537 0.171 1.685 
Local recurrence 
≤30 0.890 0.486 1.631 
1.2498 0.2636 
>30  0.354 0.077 1.615 
Second malignancy 
≤30 1.408 0.682 2.907 
1.5314 0.2159 
>30  0.305 0.028 3.383 
IDFS minus skeletal 
recurrence 
≤30 1.067 0.788 1.446 
3.2582 0.0711 
>30  0.468 0.201 1.091 
All IDFS events 
≤30 0.984 0.754 1.284 
4.4988 0.0339 
>30  0.392 0.173 0.889 
Table 3-11  Predictive IDFS component analyses – adjusted analysis of 
treatment arm versus control arm 
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3.4.8.6 Vitamin D analysis using normalised values 
Mean normalised vitamin D values by menopausal status are shown in table 
3-12.  
Menopausal 
status 
Number Mean SD IQR Range 
Pre-menopausal 404 17.75 9.00 11.13-
22.86 
3.11-
59.48 
≤5 years since 
menopause 
117 19.32 10.20 10.75-
26.19 
4.38-
57.09 
>5 years since 
menopause 
262 18.07 9.58 11.32-
22.89 
2.80-
56.96 
Status unknown 73 19.06 8.43 13.00-
24.70 
7.36-
43.10 
All patients 856 18.17 9.31 11.30-
23.79 
2.80-
59.48 
Table 3-12  Summary statistics of normalised vitamin D by menopausal 
status and overall 
 
Results for first recurrence in bone were similar to the analysis for the non-
normalised vitamin D values, with a statistically non-significant reduced risk 
for women with sufficient levels of vitamin D (HR 0.56, 95% CI 0.22-1.39; 
p=0.173). The magnitude of risk reduction appears greatest among post-
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menopausal patients (post-menopausal HR 0.369, 95% CI 0.050-2.739 vs 
non post-menopausal HR 0.642, 95% CI 0.231 – 1.782; p=0.612) however 
there appears to be a benefit to having sufficient levels of vitamin D for all 
groups. Patients with sufficient levels of normalised vitamin D appear to 
have lower risk for distant recurrence compared with those with low levels, 
however this is no longer statistically significant (HR 0.71; 95% CI 0.42 – 
1.20; p=0.181). HRs are similar for post-menopausal and non-post-
menopausal patients (0.782 vs. 0.677, p=0.803).  
 
When normalised vitamin D was analysed as a continuous variable and as 
part of a treatment interaction, the results were very similar to those of non-
normalised vitamin D (data not shown).  
The significant treatment interaction seen with non-normalised vitamin D 
levels and the predicative “all IDFS events” component analysis is no longer 
significant when using the normalised vitamin D values (≤30 HR 0.921, 95% 
CI 0.705-1.203; >30 HR 0.640, 95% CI 0.289-1.418; p=0.391).  
 
3.5 Discussion 
The baseline characteristics of the serum marker sub-population are 
comparable to that of the main AZURE trial. This is reassuring with regards 
to the outcomes of the sub-population and translating the findings back to 
the main study. 
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This work has shown that, patients with early breast cancer and increased 
bone turnover, using bone turnover markers as a surrogate, are at increased 
risk of bone metastasis at any time.  (P1NP p=0.006, 1CTP p=0.008, CTX 
p=0.009 when analysed as a continuous variable), with P1NP appearing to 
be the most sensitive of the markers studied. When analysed as a 
categorical variable, the HRs are all greater than 1, indicating the trend that 
high bone turnover can identify patients at greater risk for bone metastasis, 
however this only reached statistical significance for P1NP (p=0.03) and 
CTX (p=0.03).  Using CTX and P1NP as a composite biomarker did not add 
to the sensitivity of the individual markers. This may be partially because the 
markers are not independent, reporting on linked metabolic processes, but 
may also be due to the relatively small numbers of events in the combined 
group.  
 
This finding provides support for the hypothesis that the bone 
microenvironment, in which there is increased bone turnover in both 
formation and resorption, is a fertile soil for skeletal metastasis from breast 
cancer. By contrast with this clear association between baseline bone 
turnover markers and recurrence in bone, there was no association 
detectable between bone turnover markers and distant recurrence taken as 
a whole. It is acknowledged that, in some cases, elevation of baseline 
markers may be linked with active, but as yet undetected, bone metastases, 
however, the relatively long follow up (median 84 months) and few bone 
events in the first 2 years (<5%) when the cumulative incidence curves 
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diverge, makes it unlikely that the realised markers are simply an early 
diagnostic indication of bone metastases.  
 
Whilst the work presented here has never been done before on such a scale 
and with such a robust dataset, there is some supporting evidence from the 
published literature. Lipton et al investigated CTX in 621 post-menopausal 
early breast cancer patients in a 5-year phase III trial of tamoxifen +/- 
octreotide, median follow up 7.9 years. They demonstrated that higher pre-
treatment CTX (0.71 ng/ml cutpoint) was associated with shorter bone-only 
recurrence-free survival (RFS) as categorical variable (HR 2.8, 95% CI 1.05 
– 7.48, p=0.03)175. They also demonstrated its significance as a continuous 
variable. The trends in the present study are comparable with those of the 
Lipton study however the magnitude and significance of effect appears much 
greater in the latter work. This is likely due, in part, to the differences 
between the study populations; the Lipton study including only post-
menopausal patients, almost entirely ER positive with lower risk disease and 
greater than two thirds did not receive adjuvant chemotherapy. In view of 
these characteristics it is likely that they were at greater risk from bone 
metastasis.  
P1NP has previously been investigated in a relatively small group of mixed-
risk early breast cancer patients not participating in a specific clinic trial207. 
164 stage I-III breast cancer patients had their pre-treatment P1NP levels 
determined. The duration of follow up is unknown but a surprisingly high 
55/164 patients developed bone metastases. Adjusting for factors including 
stage, grade, ER status and chemotherapy, P1NP was significant for early 
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bone recurrence (HR 2.9, 95% CI 1.2 – 6.0; p=0.03). There are a number of 
limitations of this study including its size, unknown follow up and 
heterogonous population but there is agreement between this and the 
present study.  
A limitation of our study is that only baseline biomarker measurements were 
available for analysis and we are therefore unable to determine whether 
subsequent changes in bone turnover may also play a role. This was 
investigated by McCloskey et al who took paired serum samples at baseline 
and 1 year within the protocol of a large randomised clinical trial of oral 
clodronate versus placebo in early breast cancer127. An increase in P1NP 
between the baseline and later sample was associated with significantly 
higher incidence of bone metastases compared with patients in whom the 
P1NP remained stable or reduced. They did not demonstrate prognostic 
significance for baseline P1NP alone.  
Bone turnover markers are not prognostic for distant recurrence (any site). 
This finding suggests that the bone microenvironment status may play an 
important role in the development of skeletal metastasis from breast cancer 
but this does not necessarily translate into distant visceral metastasis. Whilst 
it has been suggested that cancer cells are attracted to the bone, perhaps 
initially as a sanctuary site where they may evade systemic therapies and 
then disseminate to the viscera, the mechanisms that are involved in the 
attraction to bone, maintaining their numbers low while dormant, 
reactivation, proliferation and then escaping are complex and dynamic50, 160. 
Identifying a marker from this process is beyond the scope of this thesis, but 
an important area for future work.  
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 The main AZURE study showed that there were significant reductions in the 
incidence of bone metastases either as a 1st recurrence (HR 0.78, 95% CI 
0.63 – 0.96; p=0.020) or at any time (HR 0.81, 95% CI 0.68 – 0.97; p=0.022) 
in the treatment group182. The work presented here shows that bone 
turnover markers are unable to identify which patients may benefit from 
treatment with zoledronic acid. However, as the effect was seen in all 
menopausal groups, perhaps this is not surprising. It remains unclear what 
the mechanism is underlying the benefits seen in AZURE in post-
menopausal women treated with zoledronic acid. We had thought that the 
benefits might be related to the higher rate of bone turnover that occurs at 
menopause however, the work in this thesis refutes this hypothesis as no 
association between bone turnover markers and the effects of zoledronic 
acid were detected. However, a number of factors may contribute to this 
result. Administration of multiple doses of a potent bisphosphonate can 
confidently be assumed to suppress bone turnover throughout the 5-year 
treatment period. This could render the baseline marker values less relevant 
in analyses of association. Additionally, bone turnover markers reflect 
activity across the skeleton as a whole whereas the amount of bone 
associated with disseminated tumour cells likely comprises only a very small 
fraction of the total skeletal metabolic activity. Finally, there is the intriguing 
possibility that the efficacy of zoledronic acid in the adjuvant setting may be 
due to a direct toxic effect on tumour cells in the bone microenvironment and 
independent of its action on bone turnover.  
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The overwhelming majority of women in this study had deficient levels of 
vitamin D. Only 8.6% and 12.1% in the control arm and treatment arm, 
respectively, had baseline levels ≥30ng/ml, the level considered necessary 
for good bone health. This is consistent with other studies that have 
demonstrated a high prevalence of vitamin D deficiency amongst a breast 
cancer population208, 209. Vitamin D deficiency is a recognised problem in 
Great Britain due to working indoors, northern climate, low dietary intake and 
obesity210. A large population study reported that 90% of sampled adults had 
levels <30ng/ml in the winter and spring and 60% were deficient all year 
round210. This is of particular concern due the finding in the present study 
that an “insufficient” level of vitamin D is prognostic for distant recurrence.  
A recent meta-analysis has shown that patients with vitamin D levels of 
>29.1 ng/ml have significantly lower breast cancer mortality compared with 
those with low levels (RR 0.58, 95% CI 0.40 – 0.85) and lower risk for breast 
cancer recurrence (RR 0.61, 95% CI 0.47 – 0.80)211.  A number of 
mechanisms have been postulated for how vitamin D affects breast cancer 
risks and outcomes including through vitamin D receptors, which control a 
variety of cellular mechanisms such as differentiation, proliferation, 
apoptosis and angiogenesis212. These effects are seen in both oestrogen-
dependent and oestrogen-independent tumours. In general, the work 
presented here agrees with the findings that patients at risk of breast cancer 
recurrence are more likely to relapse if their vitamin D levels are deficient. 
While the HR for bone as a first site of recurrence amongst women with 
sufficient levels of vitamin D is 0.5, this does not reach statistical 
significance, nor does this vary by menopausal status. However, with 
regards to any distant recurrence, women with sufficient levels are at 
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significantly lower risk, even when adjusted for menopausal status and 
treatment allocation (HR=0.6; p=0.0378). On further analysis, it appears that 
this is may be driven largely by the effect amongst non-post-menopausal 
women, though this is non-significant when analysed separately. 
Conversely, this study demonstrates that it is the post-menopausal women 
with sufficient levels of vitamin D that benefit from treatment with zoledronic 
acid but it must be borne in mind that the numbers at risk in this study are 
very low.  
Although the mechanism is not clearly understood, it is increasingly 
accepted that the patients who may benefit from adjuvant bisphosphonates 
are those who are in established menopause, either natural or induced by 
GnRH analogues. However, it is uncertain how vitamin D levels may also 
interact in this oestrogen-deficient state to improve outcomes. It has been 
shown in pre-clinical studies that calcitriol inhibits the synthesis and 
biological action of oestrogens through suppressing aromatase 
expression213. However, it is unknown whether the vitamin D-rich status 
promotes the underlying benefits of being oestrogen-deficient when 
receiving adjuvant bisphosphonates for early breast cancer. 
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4 Quantitative assessment of bone remodelling following 
adjuvant zoledronic acid in the AZURE study – 
methodology 
4.1 Introduction 
My role in chapters 4 and 5 included assisting set up of the QBS sub-
protocol in Leeds and Sheffield, alongside medical physics and nuclear 
medicine, approaching and consenting patients, co-ordinating the timing of 
scans, present for most Leeds scans, undertaking blood sampling and 
limited laboratory work, in addition to all statistical analysis in chapter 5.  
 
Despite the overall favourable safety profile of zoledronic acid, its toxicity 
has caused concern in recent years, particularly with regard to ONJ, as 
explored in chapter 2. A more recent concern is whether over-suppression of 
bone turnover has any detrimental effects, particularly in view of case report 
evidence of atypical fractures214. While benefits of bisphosphonates are 
confirmed in terms of reduced skeletal fracture and expected improved bone 
mineral density, further exploration of the degree to which bone turnover is 
affected is required. It is currently unknown what effect an intense schedule 
of zoledronic acid will have on bone remodelling, particularly with regard to 
the skeletal regional differences, degree of difference from controls and the 
duration of any effects. 
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Studies demonstrating continued bone remodelling with the zoledronic acid 
dosing schedules used in osteoporosis have been reassuring215.  However, 
it is important to consider the issue of to what extent normal bone 
remodelling may be suppressed by the more intense adjuvant dosing 
schedules, since adjuvant zoledronic acid is now becoming the standard of 
care for postmenopausal women216, 217 and many of these women will be 
long-term survivors from their breast cancer. 
4.1.1 Quantitative assessments on bone remodelling 
4.1.1.1 Bone histomorphometry 
The gold standard method for quantifying bone turnover is bone 
histomorphometry following double tetracycline labelling. The procedure for 
bone biopsy is invasive, involving extraction of a bone sample from the iliac 
crest using a trephine to obtain a cylindrical sample. This sample should 
contain internal and external layers of cortical bone in addition to an 
intermediate region of trabecular bone. The sample then undergoes an 
extensive process of preparation, cutting and staining before analysis can 
take place. The administration of tetracycline (orally or parenterally) allows 
dynamic assessment of bone metabolism. This fluorescent compound binds 
to mineralisation fronts, labelling them yellow-green under fluorescent light 
and acting as a marker for bone formation and mineralisation. Given 10-14 
days apart, 2 doses of tetracycline will allow the amount of bone formed 
during that interval to be calculated by measuring the distance between the 
2 fluorescent labels218. 
The primary limitation of this technique is the invasiveness of the procedure 
which does have potential complications including pain, bleeding, infection 
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and neuropathy. The technique only allows a single “snap-shot” in time, 
repeated biopsies would be required for assessment of response to 
treatment. In practice, double labelling with tetracycline is less useful in 
patients with highly suppressed bone turnover because of the significant 
percentage of patients showing either single labels or complete absence of 
labels. Finally, this technique only allows assessment of the specific region 
of the iliac crest. 
4.1.1.2 Biochemical markers 
As discussed in chapter 1, biochemical markers in both blood and urine are 
able to detect changes in bone turnover. To briefly recap, markers may 
either reflect resorption, including peptides from collagen degradation for 
example NTX, or formation, including peptides released during collagen 
synthesis such as P1NP. These markers have been extensively studied, are 
relatively easily measured and have reference ranges established. 
More recently, markers have been developed to reflect more specific 
aspects of bone metabolism, including TRAP 5b and α/β CTX ratio. The 5b 
isoenzyme of tartrate-resistant acid phosphatase (TRAP 5b) was originally 
developed as a cytochemical test for hairy cell leukaemia as it was the only 
blood-derived cell to exclusively express type 5 TRAP219. Shortly after, it was 
also identified as a marker of osteoclast function, with increased activity in 
metabolic and metastatic bone diseases. TRAP 5b is highly specific for 
osteoclasts, reflecting their number and thus providing complementary 
information to collagen degradation products which reflect the destruction of 
bone matrix220. It has been shown to be the most sensitive marker for 
measuring change, allowing precise measurements in individuals221. Serum 
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TRAP 5b has been reported as responding to bisphosphonate therapy in 
post-menopausal women222, in addition to being elevated amongst breast 
cancer patients with bone metastases223-226.  
Once laid down, type I collagen is subject to a series of modifications that 
may influence bone strength including enzymatic cross-link formation and 
non-enzymatic glycation cross-linking, racemisation and isomerisation227. 
The ratio between the native α and isomerised β CTX measured in urine by 
specific immunoassays gives an estimate of the extent of type I collagen 
isomerisation in bone tissue 228.  In children, equilibrium between the 2 forms 
is not achieved due to the high rate of bone modelling, however, in adults, 
the rate of remodelling is slower than the rate of isomerisation, allowing 
equilibrium to be achieved. There are some clinical situations in which there 
is a localised increase in bone turnover for example Paget’s disease and 
malignant bone disease, where again the equilibrium cannot be achieved 
resulting in higher α/β CTX ratio229, 230. This alteration is associated with a 
disorganised collagen matrix and increased fragility which may consequently 
cause increased fracture risk231, 232. Pre-clinical and clinical studies have 
demonstrated a decrease in α/β CTX ratio following bisphosphonate 
administration233. Thus, monitoring changes of α/β CTX may provide 
information on bone quality under long term zoledronic acid treatment which 
is not captured by BMD and conventional bone turnover markers. 
Whilst bone markers are relatively easily measured in blood or urine using 
reliable, well-validated assays, they do have some disadvantages. 
Measurements on individual patients can be unreliable due to the day-to-day 
variations. Additionally, measurements in serum or urine reflect the degree 
- 123 - 
of bone remodelling occurring throughout the entire skeleton but are not 
useful for investigating specific skeletal sites of interest. 
 
4.1.1.3 Dual-energy x-ray absorptiometry (DXA) 
DXA has an important role in the early detection and monitoring of 
osteoporosis. It obtains a quantitative assessment of bone mineral density 
(BMD) and was a significant improvement on the assessment of bones 
compared to plain radiographs which rely purely on subjective, visual 
interpretation. Bone densitometry calculates bone mineral density in 
numerical units, providing a quantitative representation on bone mineral 
losses.   
 
DXA uses highly collimated beams of low-energy x-rays. These beams are 
able to pass through soft tissues and bone and are captured by a detector 
placed on the opposite side. The intensity of the beam exiting the body is 
captured on the detector and is inversely related to the areal density (g cm-2) 
of the body part being visualised. By measuring the attenuation of X-ray 
beams at two different energies, the areal densities of two types of tissue 
(bone and soft tissue) can be measured. For quality control processes, 
phantoms are scanned regularly. For example, the European Spine 
Phantom consists of 3 simulated vertebrae and is constructed to give BMD 
values of 0.5, 1.0 and 1.5g/cm2 234. 
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The hip and spine are usually chosen to evaluate fracture risk. As the spine 
has the most trabecular bone content, it best represents the patient’s bone 
metabolism and therefore, vertebral bodies are generally regarded as being 
better for monitoring response to treatment than other skeletal sites215. 
DXA devices compare the BMD result of an individual patient with the BMD 
data of the young normal populations (T-score) or with the BMD data of an 
age-matched control group (Z-score). These are expressed as units of 
standard deviation from the mean. Patients can then be classified according 
to whether they are normal, osteopaenic or osteoporotic at that particular 
site (WHO Classification, figure 4-1). 
 
 
 
 
 
 
 
 
The National Health and Nutrition Examination Survey III (NHANES III) 
compiled a standard set of normal bone density measurements of the hip for 
different gender, ethnicity and age groups within the U.S. with which a test 
result can be compared235. More recently, the FRAX tool has been 
developed by Professor John Kanis and colleagues at the University of 
Sheffield to evaluate risk of fracture, integrating clinical risk factors specific 
Normal  T-score ≥-1.0 
Osteopaenic  T-score -1.0 to -2.5 
Osteoporotic  T-score ≤ -2.5 
Figure 4-1 WHO Classification based on BMD 
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to the patient with BMD at the femoral neck to give a 10 year probability of 
fracture (hip or major osteoporotic fracture)236. Several risk factors are taken 
into account: low body mass index (BMI), previous fragility fracture, parental 
history of hip fracture, glucocorticoid treatment, current smoking, alcohol ≥ 3 
units per day, rheumatoid arthritis, other secondary causes of osteoporosis. 
DXA scanning along with appropriate use of risk scoring can provide 
extremely useful diagnostic and treatment response information. The scans 
are quick, give a low radiation dose and can be used to measure sites such 
as spine, hip and forearm. However, rates of change of DXA measured BMD 
are slow and even at a site such as the spine it can take several years to 
measure the rate of change. It is also possible to measure total body DXA 
which is of interest by providing a comprehensive view of changes across 
the whole skeleton (figure 4-2). Whole body scans measure bone mineral 
content (BMC) and average BMD in the total skeleton in addition to 
subregions skull, spine, arm, legs and pelvis. Furthermore, they can 
measure body composition, including total body and regional measurements 
of fat and lean. 
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Figure 4-2  Example of image capture from whole body DXA scan 
 
4.1.1.4 Quantitative radionuclide studies 
Due to the affinity of bone for phosphate and phosphate tracers, their 
skeletal uptake has been investigated for their role in the detection of 
metabolic bone disorders. Quantitative radionuclide studies use short half-
life radiopharmaceuticals such as 99mTc-methylene diphosphate (99mTc-
MDP) to reflect the combined effects of bone blood flow and osteoblastic 
bone activity on the bone tracer kinetics237. The combination of blood 
sampling and gamma camera imaging allows quantitative investigation of 
bone tracer kinetics and there have been many developments in techniques 
over the last 3 decades238. 
Initial methods included the 24-hour 99mTc-MDP whole body retention (WBR) 
test239. This technique is based on the compartmental model shown in figure 
4-3. 
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Figure 4-3 Compartmental model of tracer kinetics following 
intravenous injection 
 
Approximately 2 hours following intravenous (i.v.) injection of 99mT-MDP, the 
tracer will have reached equilibrium with the extracellular, extravascular fluid 
compartment and is either cleared to bone or renally excreted. Kbone (mls 
min-1) is the rate constant of the plasma clearance of the tracer to the bone 
mineral compartment (of whole skeleton) while Krenal (mls min
-1) reflects the 
clearance though the kidneys.  
 
The value of k4 (see figure 4-3) has been shown to be negligible
240. 
Therefore, by 24 hours the WBR will approximate to the figure calculated 
from the division of the available tracer between bone and kidneys in the 
ratio of their respective plasma clearances.  
24-hour WBR = Kbone/(Kbone + Krenal) 
The 24-h WBR therefore depends on the patient’s GFR as well as the 
plasma clearance to bone. 
 
4.1.1.4.1 Use of gamma camera 
The previous method described used a whole-body counter, taking a 
baseline count at 5 minutes after injection and repeated at 24 hours. 
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However, these counters are now no longer widely available. Consequently, 
a number of methods using a dual-headed gamma camera have been 
described which combine counts from anterior and posterior views. This 
combination of counts reduces the attenuation errors due to the 
redistribution of tracer in the patient’s body during the period of 
measurement. Quantifying the bone scan image must take into account the 
fact that by 4 hours post injection, around half of the non-excreted 99mTc-
MDP is in the soft tissue, not bone. A method for this was described by 
Brenner et al 241. By drawing a region of interest (ROI) around the adductor 
muscles of both thighs, an area that excludes any signal from bone can be 
selected. This count is performed at the time of the baseline whole body 
scan, commenced 3 minutes after injection, when the assumption is made 
that 100% of injected tracer is still in the soft tissue. These counts can be 
used to infer the whole body soft tissue retention on later scans and 
subtracted from the WBR to derive the bone uptake (see figure 4-4). 
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4.1.1.5 Measurement of skeletal plasma clearance 
As mentioned previously, the measurement of 99mTc-MDP bone plasma 
clearance (Kbone) to either whole skeleton or a defined region of bone is a 
more flexible and more informative measurement than the 24-hour WBR for 
monitoring response to treatment because it can be measured regionally 
and is independent of GFR. There are several methods for measuring this. 
 
4.1.1.5.1 The area under the curve (AUC) method 
This method uses the equation Ktotal = (Kbone + Krenal) and assumes that the 
rate constant k4 is sufficiently small to be disregarded and therefore the total 
clearance of the free 99mTc-MDP can be calculated by dividing the amount of 
Soft tissue retention 
ST(t) = 100% x Add(t)/Add(3 min) 
Urinary excretion 
U(t) = 100% - WBR(t) + Bladder(t) 
Bone uptake 
B(t) = 100% - ST(t) – U(t) 
t, time since injection; ST, soft-tissue retention as a percentage of injected dose; Add, 
counts in adductor muscle ROI decay corrected to time of injection; U, urinary excretion as 
a percentage of injected dose; WBR, whole-body retention as a percentage of injected 
dose calculated from the decay corrected whole-body counts; Bladder, urinary bladder 
activity as a percentage of injected dose; B, bone uptake as a percentage of injected dose. 
Figure 4-4 Equations used for the calculation of soft-tissue 
retention, urinary excretion and bone uptake of 99mTc-MDP 
using the standard Brenner gamma camera method. 
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tracer injected (Q) by the area under the plasma clearance curve, analogous 
to the calculation of GFR from a 51Cr-EDTA plasma clearance curve242.  The 
measurement is complicated by the degree of protein binding, which can 
reach 70% at 24 hours following injection243. It is crucial to measure free 
MDP as the bound fraction is not available for skeletal uptake. 
 
 
 
where Pfree tracer
99mTc−MDP represents the plasma concentration of free 99mTc-MDP 
at time t. The use of ultrafiltration as a method of measuring the plasma 
concentration of free 99mTc-MDP has been validated by Moore et al244. As 
the renal clearance of free 99mTc-MDP is the same as that of 51Cr-EDTA the 
value of Kbone can be found by subtracting the GFR figure measured for 
51Cr-
EDTA from the Ktotal figure measured using the previous equation. 
Kbone = Ktotal – GFR 
These plasma clearance curves are measured by multiple blood sampling 
between 5 minutes and 4 hours after tracer injection. 
 
 
4.1.1.5.2 Modified Brenner method 
In the Brenner method, soft tissue retention of 99mTc-MDP is measured by 
imaging the adductor muscles in both thighs. In the modified method a 
dynamic study of this ROI is performed at the time of injection followed by a 
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series of 2 minute static images acquired at 1, 2, 3 and 4 hours with the 
same ROI copied onto the anterior and posterior images. A plot of the 
geometrical mean counts, after correction for decay, as a function of the 
area under the free 99mTc-MDP plasma curve can be constructed (figure 4-5) 
 
 
Figure 4-5 Curve showing the measurement of the total (renal plus 
bone) plasma clearance of free 99mTc-MDP using the modified 
Brenner method. 
Taken from Quantitative Studies of Bone Using 
99m
Tc-MDP Skeletal plasma 
Clearance
245
, with permission. 
  
 
As Moore et al point out, there are 2 problems with the assumptions required 
for the original Brenner method. Firstly, the baseline whole body scan, even 
if started only 3 minutes after injection, will be misleading, as already about 
10% of injected tracer will have been excreted via kidneys or cleared to bone 
due to the time it takes for the scan to reach the adductor muscles. 
Secondly, at such an early time-point, the tracer in soft tissue will have not 
yet reached equilibrium with tracer in the vascular compartment. They 
therefore developed a modified method in which the first soft tissue image is 
delayed until 1 hour after injection to ensure full equilibrium (figure 4-4)238. 
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The value of Ktotal can be found by extrapolating the straight line fit of linear 
decrease in percentage injected dose to find the intercept on the horizontal 
axis. The total plasma clearance through the kidneys and the skeleton can 
be calculated from the equation: 
Ktotal = Q / AUC1 
Renal plasma clearance of free 99mTc-MDP can be measured from a similar 
plot of the gamma camera measurements of WBR corrected for counts in 
the bladder and kidneys against AUC to find the intercept on the horizontal 
axis AUC2. Renal clearance can be calculated as  
Krenal = Q / AUC2 
Kbone can be found by Ktotal – Krenal (see figure 4-6). 
 
Figure 4-6 Plots of WBR and soft-tissue retention of 99mTc-MDP against 
AUC to estimate Ktotal and Krenal using the modified Brenner 
method 
Taken from Quantitative Studies of Bone Using 99mTc-MDP Skeletal plasma Clearance
245
, 
with permission 
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4.1.1.5.3 Patlak Plot method 
This method allows values for Kbone to be determined for either the whole 
skeleton or any chosen subregion. The method was originally developed as 
a theoretical model of blood-brain exchange, but the model is general and 
assumes linear transfer kinetics246. A simplified description of the 
mathematical principles is given elsewhere247. In brief, tracer uptake at time 
T can be measured for a ROI drawn on the bone scan (figure 4-7).  
 
 
Figure 4-7  Displays regions of interest for measurement of Kbone 
values for: spine, pelvis, spine, arms and legs (a) and; mandible 
and calvarium (b).  
Taken from Moore A et al
248
, with permission. 
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This uptake is composed of both tracer uptake in bone for the ROI and 
tracer uptake in soft tissue: 
 
Total Uptake = Bone Uptake + Soft Tissue Uptake    (Equation 1) 
 
Bone uptake in equation 1 is equal to Kbone multiplied by the integral of the 
plasma concentration of free tracer from t = 0 to t = T. Once equilibrium is 
reached between tracer in the circulation and tracer in soft tissue (at about 2 
hours after injection) then the soft tissue uptake in equation 1 is equal to the 
volume of distribution of tracer in the ROI multiplied by the total plasma 
concentration of tracer (bound plus free tracer). By substituting these two 
terms for bone and soft tissue uptake in equation 1 and dividing through by 
the total plasma concentration, the result is an equation for a straight line: 
Y = m X + c 
The slope m is the value of Kbone and the intercept c is the volume of 
distribution (figure 4-8). 
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Figure 4-8 Patlak plot using 99mTc-MDP WBT and plasma data. Kbone 
was estimated from the straight-line fitted to the 2-, 3- and 4-hour 
time points. Points at 10 minutes and 1 hour deviate from the line as equilibrium 
has not yet been reached. 
 
The 3 methods have been compared in a study reporting the baseline Kbone 
values in post-menopausal women participating in a clinical trial of 
teriparatide 238. They report mean values of Kbone ± SD as: i) 30.3 ± 6.4 
mls/min using the AUC method; ii) 31.3 ± 5.8 mls/min using the modified 
Brenner method and ; iii) 35.7 ± 5.8 mls/min using the Patlak plot method. 
They conclude that there is close agreement between the AUC and modified 
Brenner methods, with no statistically significant difference between their 
results. However, the Patlak figure was higher than the other measurements 
(p = 0.001). When they re-examined the graphs, they identified that the 
slope for the 3-4 hours points was shallower than the 2-4 points. 
Recalculation based on using the 3-4 hours points brings the mean Kbone 
value to 33.0 ± 6.9 mls/min which was no longer significantly different. While 
this may be more accurate, the authors do point out that it would require a 6-
hour measurement to compensate for the shorter time baseline, which would 
make the method less feasible. 
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4.2 Trial design 
4.2.1 Main BoHFAB study 
As the main BoHFAB study does not form part of this thesis, it will not be 
described in detail. However, it is summarised below to put the quantitative 
bone scan (QBS) sub-study into context. 
244 patients (approximately equally drawn from the zoledronic acid and 
control arms) who have completed the 5-year main AZURE trial were 
recruited from UK centres.  It is estimated that 60% patients who entered the 
main AZURE study were eligible for the main BoHFAB study. Patients were 
to be recruited within 3 months of completion of the main study.  
 
Inclusion criteria: 
• Participation in either the control arm or the zoledronic acid arm of the 
main AZURE study. 
• Ability to perform first DXA lumbar spine and total hip measurement 
on this study within 3 months of the 5 year follow-up visit on the AZURE 
study. 
Exclusion criteria:  
• Presence of metastatic or recurrent breast cancer. 
• Use of bisphosphonates other than on the AZURE study.   
• Severe physical or psychological concomitant diseases that might 
impair compliance with the study protocol. 
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• Inability to obtain reliable DXA information due to pre-existing 
pathology or prior surgery 
• Pregnancy or breast-feeding at study entry. 
 
At entry to the main BoHFAB study, patients in the control arm will have a 
DXA BMD assessment of lumbar spine and total hip. These scans were 
performed on either a GE-Lunar (GE-Lunar, Madison, WI) or Hologic 
(Hologic Inc., Bedford, MA) machine, depending on site. GE-Lunar and 
Hologic machines are calibrated differently and the spine and hip BMD data 
were pooled after converting them to a common scale (referred to as 
standardised BMD) based on the scans of the European Spine Phantom. 
The femoral neck BMD, together with the clinical risk factors which are 
recorded on the FRAX Questionnaire (Appendix 4) permits their 10-year 
fracture risk to be calculated by the FRAX algorithm with treatment as 
indicated by reference to the National Osteoporosis Guideline Group 
(NOGG, www.shef.ac.uk/NOGG).  Patients identified on study as being at 
high fracture risk were referred to their local osteoporosis centre for 
treatment advice and were followed up, but excluded from further data point 
analyses.  If osteoporosis is detected in a patient from the zoledronate arm, 
they will be referred to their local osteoporosis centre for treatment advice 
and will be followed up, but excluded from further data point analyses.   
 
The following assessments will be carried out: 
• Measurement of BMD by DXA scan at lumbar spine and total hip 
(including femoral neck) at study entry, 12, 24 and 60 months 
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• Bone markers (NTX, P1NP, TRAP-5b and α/β CTX) at study entry, 6, 
12, 24, 36, 48 and 60 months.  
• Skeletal health questionnaire at study entry 
• Recording of symptomatic fractures occurring on study (vertebral and 
non-vertebral, the latter to include femoral neck, radius or other). 
 
Endpoints: The primary endpoint is a 2.5% difference in the mean 
percentage change in lumbar spine (L1-4) BMD at 24 months between the 
zoledronic acid and control arms.  
Secondary endpoints are:  
• The difference in mean percentage change in total hip BMD at 24 
months between the zoledronic acid and control arms 
• The difference in mean percentage change in lumbar spine BMD and 
in total hip BMD at 12 and 60 months  
• The difference in mean percentage change in bone markers at 6, 12 
and 24, 36, 48 and 60 months between the zoledronic acid and control arms 
• The difference between the zoledronic acid and control groups at 
study entry in the following: mean BMD at lumbar spine; mean BMD at total 
hip; mean NTX, mean P1NP, serum Trap 5b and urinary α and β CTX 
 
The study schema (including sub-study) is shown in figure 4-9. 
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Figure 4-9   BoHFAB study schema including main and sub-studies   
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4.3 Quantitative bone scan sub-study design 
4.3.1 Aims of study 
Whilst studies with the zoledronic acid dosing schedules used in 
osteoporosis have been reassuring, it is important to consider the issue of to 
what extent normal bone remodelling may be suppressed by the more 
intense adjuvant dosing schedules. This will be addressed in the quantitative 
bone scan (QBS) sub-study. 
4.3.2 Patients and recruitment 
This sub-study was carried out in 40 patients (equal numbers from the 
control and zoledronic acid arms) drawn from those patients in the main 
BoHFAB study who were recruited from the Sheffield/Leeds centres. Written 
informed consent was taken specifically for the sub-study, in addition to the 
consent taken for the main BoHFAB study. Although the sub-study will be 
continued for 5 years, this report refers to the first two years, which includes 
the primary endpoint. 
 
4.3.3 Assessments  
4.3.3.1 Quantitative bone scan methodology 
Patients undergo QBS at baseline, 12 months, 24 months and 60 months 
from consent to the sub-study. The following procedure was used for each 
QBS investigation: 
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Pre-scan checks 
1. Identify the patient following the local protocol. 
2. Measure the patient’s height and weight – these are used to estimate 
their plasma volume and subsequently the initial plasma activity 
concentration of 99mTc-MDP. 
3. Measure the activity of the 99mTc-MDP syringe in an assay calibrator, 
recording the exact time of the measurement. 
After the study commenced it was realised that the Leeds and Sheffield 
centres were using different 99mTc diphosphonates. Leeds were using 99mTc-
HMDP while Sheffield were using 99mTc-MDP. The statistical plan was 
therefore altered to allow for the systematically higher values of Kbone 
measured using 99mTc-HMDP. 
 
Radioisotope administration 
1. Administer the tracer, 99mTc-MDP (~600 MBq) peripherally via an 
indwelling venous cannula with a 3-way tap. In the event of 
extravasation the test should be abandoned, as this will make the 
kinetics of the tracers unpredictable. 
2. Record the exact mid-point time of the administration. 
3. To promote voiding the participant should be encouraged to drink 
~300mL of fluid per hour  
4. Measure the residual activity left in the 99mTc-MDP syringe in an 
assay calibrator, recording the exact time of the measurements.  
Dispose of the syringe in a designated sharps bin. 
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Blood sampling 
1. Venous blood samples are taken at, or as close as possible to: 5, 20, 
60, 120, 180 and 240 minutes post injection. To ensure there is no 
contamination of the samples they should be taken from a location 
other than the injection site, preferably from the contralateral arm 
2. 6 - 7mL whole blood taken to ensure 1mL of whole plasma and 1mL 
of protein free plasma can be assayed – place the blood in a green 
top (sodium heparin) collection tube. 
3. Record the exact mid-point time of each blood sample. 
4. Disposed of all contaminated waste in the designated bins. 
 . 
Gamma camera imaging 
This QBS protocol should be adopted on a dual-headed gamma camera. 
1. Scans were acquired at, or as close as possible to: 10, 60, 120, 180 
and 240 minutes post injection. 
2. The patient encouraged to empty their bladder before each scan is 
started.  
3. Immediately before acquiring each whole body scan, a simultaneous 
anterior and posterior two-minute static scan of the thighs was 
acquired. This is used to assess soft-tissue retention and is required 
for the modified Brenner method of analysis. 
4. Then acquire a simultaneous anterior and posterior whole body bone 
scan - note a quicker than normal scan speed will be adopted 
25cm/min. 
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5. Immediately after acquiring each whole body scan a 5-minute static 
lateral skull view was acquired. 
6. The exact start time of each study was recorded. 
7. For the later scans (i.e., 60 minutes scan onwards) the participant 
was reproducibly positioned, aided by: 
a. Noting down the position of their head on the couch 
b. Providing the same head (lower back, leg etc) support during 
each scan 
c. Tying their feet together 
d. Using a Velcro wrap to ‘restrain’ their arms by their side. 
8. A diagnostic level scan was acquired at 3.5 hours post injection, with 
a scan speed of 10cm/min. 
 
Sample counting 
1. Centrifuge the whole blood for 10 minutes at 2000 rpm. 
2. To allow corrections for pipetting inaccuracies, all counting tubes (and 
their tops) were weighed empty and then again after pipetting. 
3. Pipette 1mL of plasma into a counter tube and label appropriately. 
4. Pipette at least 2mL of plasma into a 10-kDa filtered tube (Amicon®-
Ultra: Cat No. UFC801096) 
5. Centrifuge all the filtered tubes for 40 minutes at 2000g. 
6. Pipette 1mL of ultrafiltrate (i.e. protein free plasma) into a counter 
tube and label appropriately. 
7. All contaminated waste was disposed of in the designated bins. 
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Preparing the standard 
1. Radiopharmacy to dispensed ~10-80 MBq from the stock solution 
used for the patient’s administration, into a syringe. 
2. The activity was measured in an assay calibrator, recording the exact 
time of the measurement. 
3. Introduce the standard solution into a 1 litre volumetric flask, add 
water until the bottom of the meniscus is at the 1 litre reference point 
and mix well.  
4. To allow corrections for pipetting inaccuracies, weigh all counting 
tubes (and their tops) empty and then again after pipetting. 
5. Pipette 1mL of standard solution into three counting tubes and label 
appropriately. 
6. Measure the residual activity left in the 99mTc-MDP standard syringe in 
an assay calibrator, recording the exact time of the measurement.    
 
Gamma counter 
1. Pipette three 1mL water samples for background sample counting 
and label appropriately – pipetting accuracy is not essential so the 
samples do not need to be weighed. 
2. Batch the following samples into different trays, placing them in the 
counter in the following order: 
i. Whole plasma, 
ii. Protein free plasma, 
iii. Standard 
iv. Water i.e. background  
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3. Count the samples using protocol 4 – i.e.140keV +/-10% for 20 
minutes. 
 
Preparation of individual spreadsheets for data analysis 
An individual spreadsheet was prepared for each QBS study performed 
comprising all collected data, timings of interventions and required 
corrections to allow calculation of Kbone by the 3 different methods and 
regional values by Patlak Plot method (please see sample in appendix 5). 
ROIs are drawn around the skull, pelvis, spine, arms, legs, calvarium and 
mandible. The numbers of pixels and counts for each ROI, and whole 
skeleton, are recorded in the spreadsheet. 
 
4.3.3.2 DXA scan methodology 
Measurements were made at lumbar spine, total hip (which also allows BMD 
at femoral neck to be calculated) and whole body for BMD assessment and 
BMC. Matching the QBS ROIs with the whole body DXA regions allows the 
normalisation of bone plasma clearance to BMC (mls min-1 per gram of 
bone), considered a more accurate assessment than Kbone (mls min
-1) alone. 
All participating centres already had access to a DXA bone densitometry 
service using either Hologic or GE-Lunar densitometers. Spine and hip DXA 
scans were carried out locally, but centrally coordinated by the Osteoporosis 
Centre in Sheffield. This centre provided standard operating procedures to 
each centre, as well as the standard European Spine phantom (ESP) to 
allow cross-calibration. However, all total body DXA scans were performed 
on GE-Lunar densitometers in either Leeds or Sheffield on the day of the 
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QBS scan and the BMD and BMC values from these scans were not cross-
calibrated with the ESP. 
 
The DXA scanners were regularly checked by scanning of phantoms 
according to the quality control standards of the DXA scanner manufacturer. 
It is important that follow-up BMD scans are performed on the same 
machine as used for the baseline scans.  Where this was not possible, for 
example, because of centres upgrading or changing their densitometer, 
cross-calibration was performed to enable interpretation of follow-up results. 
A single ESP calibration phantom was used for the study and was sent to 
each centre in turn.  In addition, each centre received a detailed SOP in DXA 
measurement for the study and was asked to send regular QA 
measurements from their DXA scanner to Sheffield for the duration of the 
study.   All DXA scans were transmitted electronically in a fully anonymised 
format to the Sheffield Osteoporosis Centre.  
 
4.3.3.3 Bone marker methodology 
Samples for bone marker measurement were collected and stored according 
to strict SOPs provided by the Sheffield Metabolic Bone Unit.  Samples were 
stored locally (-80°C) for up to one year, before being transferred to central 
storage (-80°C) at the Sheffield Metabolic Bone Unit (Fatma Gossiel).  
Measurements in Sheffield were carried out in batches, as this was most 
economical and subject to least intra-assay variation.  NTX was measured in 
second morning voided urine samples by a chemiluminescent assay using a 
Vitros ECI analyser52 and expressed relative to urinary creatinine.  P1NP 
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was measured in serum using radioimmunoassay as described in chapter 3 
(Orion Diagnostics Oy, Finland).  
 
Serum Trap 5b was measured by a specific ELISA (Immunodiagnostic 
Systems) and Urinary α and β CTX was measured by the Urine ALPHA 
CrossLaps ELISA® and the Urine BETA CrossLaps® ELISA, respectively. 
These are based on highly specific monoclonal antibodies against a specific 
amino acid sequence.  
 
4.3.3.4 Other assessments 
As part of the main study, a skeletal health questionnaire, developed in the 
Sheffield Osteoporosis Centre which has been verified over several years, 
was used (FRAX), combining the recorded family history of osteoporosis, 
previous fractures, concomitant medication and other data from the WHO 
Risk Factor Questionnaire (Appendix 4) with the femoral neck BMD to 
calculate 10-year fracture risk. The questionnaire is attached in appendix 4. 
Additionally, symptomatic fractures were recorded as part of the main 
AZURE study for comparison between the zoledronic acid-treated patients 
and control patients. Symptomatic fractures occurring during the study were 
recorded and the recording included if traumatic or low trauma fractures and 
site of fracture (vertebral and non-vertebral, the latter to include femoral 
neck, radius or other). 
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Ethical approval was sought and obtained from the West Midlands Research 
Ethics Committee (approval letter in appendix 6). 
 
4.3.4 Endpoints 
 A significant difference in the baseline measurements of Kbone/BMC 
between the treatment and control groups  
 A significant change in Kbone/BMC from baseline at 1 and 2 years (and 
5 years within the trial but out with the scope of this thesis) using 
patients as their own controls. 
 A significant difference in BMD between the two groups 
 A significant difference in mean NTX, P1NP, TRAP5b and α/β CTX 
NP, CTX, 1CTP at baseline, 12 months and 24 months between the 
two groups. 
 
4.3.5 Statistical plan 
4.3.5.1 Sample size calculations 
From earlier studies in which the technique was developed for 
osteoporosis238, using a population standard deviation of 30%, and 80% 
power, 30 patients (both groups) are required to show a difference in Kbone of 
20% (p < 0.05) at baseline. Similar power calculations based on a 
measurement precision of 20% show that 30 patients are also required to 
detect 20% change in Kbone from baseline, using patients as their own 
controls at 1,2 or 5 years. Allowing for 25% drop out, 40 patients will 
therefore be recruited.  
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4.3.5.2 Statistical analysis 
All statistical analysis was performed using IBM SPSS Statistics 21. All 
endpoints were subjected to statistical significance testing with a 5% (2-
sided) significance level. Comparisons with the control group at each 
timepoint (baseline, 12 month, 24 months) were analysed using a linear 
regression model adjusting for treatment allocation (control versus treatment 
arm) and tracer (HMDP versus MDP). The regression beta coefficient is 
used to estimate the degree of difference between the 2 groups and 95% CI 
for the coefficients are also reported. The Student’s T-test was additionally 
used to compare mean values where necessary.  
Change from baseline was subject to similar statistical testing, using patients 
as their own controls where appropriate.  
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5 Quantitative Bone Scan – results 
5.1 Patient participation 
The recruitment period was from September 2009 until January 2011. 
Patients were eligible if they participated in AZURE at centres in Leeds, 
Huddersfield, Sheffield or Chesterfield. There were 73 eligible patients 
across the 4 sites that were all approached, excluding 1 who was lost to 
follow up. Of the remaining 72, 14 declined both the main study and sub-
study, 18 consented for the main study only (2 due to lack of availability for 
QBS) and 40 consented to the QBS sub-study. Of the 40 patients who 
consented, 37 were included in the analysis. 1 was excluded due to poor 
venous access and 2 were excluded due to relapse disease. Baseline 
characteristics for these 37 patients are shown in table 5-1. There was no 
significant difference between the two groups, with the exception of age and 
bone mineral density. Participants in the treatment arm were significantly 
older than patients in the control arm by a mean of 6.5 years. At baseline, 
participants in the treatment arm had a significantly higher T-score at both 
the hip (0.28 vs. -0.59, p=0.029) and the spine (0.21 vs. -1.04, p=0.003). 
Significantly fewer patients in the treatment arm were classified as either 
osteoporotic or osteopaenic compared with the control arm (26% vs. 73%, 
p=0.017).  
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Characteristic Control (n=18) ZOL (n=19) Significance 
Age in years (range) 53.0 (39-71) 59.5 (45-73) P=0.030 
Menopausal status, n (%) 
≥ 5 years postmenopausal 
< 5 years postmenopausal 
Premenopausal 
 
 11 (61) 
4 (22) 
3 (17) 
 
15 (79) 
3 (16) 
1 (5) 
 
 
P=0.421 
Endocrine therapy use, n (%) 
AI 
Tamoxifen 
No endocrine therapy 
 
11 (61) 
9 (50) 
5 (28) 
 
14 (74) 
9 (47) 
5 (26) 
 
P=0.321 
P=0.567 
P=0.605 
Chemotherapy use, n (%) 
Yes  
No 
 
17 (94) 
1 (6) 
 
19 (100) 
0 
 
P=0.486 
 
BMI (kg/m
2
; mean ± SD) 26.1 ± 4.0 27.2 ± 4.5 P=0.436 
Mean T score 
Hip 
Spine 
 
-0.59 
-1.04 
 
0.28 
0.21 
 
P=0.029 
P=0.003 
Mean Whole body BMD (mg m
-2
; SD) 1021 (114) 1155 (134) P=0.003 
WHO Classification, n (%) 
Osteoporotic 
Osteopaenic 
Normal 
 
1 (6) 
12 (67) 
5 (28) 
 
0 
5 (26) 
14 (74) 
 
 
P=0.017 
GFR (mls min
-1
; SD)* 74.7 (13.5) 71.9 (14.4) P=0.538 
Table 5-1   Baseline characteristics of 37 patients include in baseline 
analysis. 
- 152 - 
 
5.2 Baseline results 
37 baseline QBS were performed between Leeds and Sheffield. The tracer 
used by the Sheffield nuclear medicine department was MDP while Leeds 
nuclear medicine used HMDP, as discussed in chapter 4. 
 
5.2.1 Whole body kbone as calculated by 3 methods  
Mean Kbone was significantly suppressed at baseline in the treatment arm 
compared with the control arm when using the modified Brenner method, 
observed with both MDP and HMDP studies and using the Patlak plot 
method for HMDP studies (table 5-2). The trend for suppressed Kbone in the 
treatment arm compared with the control arm was also observed when using 
the AUC method, however this was non-significant.  
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WHOLE SKELETON Control (SD)(n) ZOL (SD)(n) Significance 
Mean Mod. Brenner 
Kbone(ml min
-1
) 
MDP  
HMDP 
 
 
28.7 (5.3)(9) 
 
 
20.7 (6.7)(9) 
 
 
P=0.013 
34.3 (5.9)(9) 26.7 (3.9)(10) P=0.006 
Mean Patlak Plot Kbone(ml 
min
-1
) 
   
MDP 30.6 (5.8)(9) 26.5 (6.4)(9) P=0.173 
HMDP 39.2 (5.3)(9) 33.6 (6.9)(10) P=0.061 
Mean AUC Kbone(ml min
-1
)    
MDP 30.0 (6.0)(9) 23.6 (11.0)(9) P=0.149 
HMDP 35.1 (7.3)(9) 32.1 (7.1)(10) P=0.372 
Table 5-2   Mean baseline whole skeleton kbone 
 
 
5.2.2 Whole body kbone/BMC by 3 methods  
Kbone/BMC was significantly suppressed in the treatment arm compared with 
the control arm when calculated by all 3 methods and observed for both 
MDP and HMDP studies (table 5-3).  
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WHOLE SKELETON Control (SD)(n) ZOL (SD)(n) Significance 
Mean Mod. Brenner 
Kbone/BMC (ml min
-1
 g
-1
) 
MDP  
HMDP 
 
 
0.012 (0.002)(9) 
 
 
0.008 (0.003)(9) 
 
 
P=0.001 
0.015 (0.002)(9) 0.011 (0.001)(10) P<0.001 
Mean Patlak Plot 
Kbone/BMC (ml min
-1
 g
-1
) 
   
MDP 0.013 (0.003)(9) 0.010 (0.002)(9) P=0.018 
HMDP 0.018 (0.002)(9) 0.014 (0.002)(10) P=0.001 
Mean AUC Kbone/BMC (ml 
min
-1
 g
-1
) 
   
MDP 0.013 (0.002)(9) 0.009 (0.004)(9) P=0.020 
HMDP 0.016 (0.003)(9) 0.013 (0.003)(10) P=0.056 
Table 5-3  Mean Kbone/BMC for whole skeleton by the 3 methods 
 
In addition to the suppression observed in the whole skeleton, all sub-
regions studied by the Patlak plot method displayed suppression of 
Kbone/BMC the treatment arm compared with the control arm (figures 5-1A 
and B and 5-2; Kbone/BMC data not available for the mandible and calvarium 
due to no BMC date possible, therefore Kbone data displayed). This was 
observed for both tracers.  
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Figure 5-1 Kbone/BMC results for whole body (WB) and regions by arm 
of study for 99mTc-MDP (A) and 99mTc-HMDP (B) calculated by Patlak 
Plot method. 
 
 
Figure 5-2  Kbone results for calvarium and mandible. (Mandible results 
have been scaled up by x 5) 
 
 
The degree of suppression in Kbone/BMC amongst treatment patients was 
statistically significant at all sites apart from the legs: skull (p=0.002); spine 
(p<0.001); pelvis (p<0.001); arms (p=0.020); legs (0.096); calvarium and 
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mandible (no data available) (figure 5-3A). This is most profound in the 
pelvis and spine, with the least effect in the legs. 
The tracer used was also an independent variable predicting for Kbone/BMC 
values using the Patlak plot method (p<0.001) and modified Brenner method 
(p<0.001). Kbone/BMC was statistically significantly greater in studies using 
HMDP compared with those using MDP for the whole body and all skeletal 
regions, with the exception of the legs (figure 5-3B).  
 
Figure 5-3 Regression coefficients for treatment arm (A) and tracer (B) 
calculated by linear regression analysis on baseline Kbone/BMC studied 
by Patlak analysis 
 
 
5.2.3 Bone markers 
Mean baseline NTX, P1NP, TRAP5b and α/β CTX values were all 
statistically significantly suppressed in the treatment arm compared with the 
control arm (table 5-4). Linear regression analysis confirmed this finding, the 
degree of suppression in the treatment arm illustrated in figure 5-4.  
 Control (SD)(n) ZOL  
(SD)(n) 
Significance 
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Mean NTX (nmol BCE mmol 
Cr-1) 
 
42.5 (17.6)(17) 18.3 (6.2)(17) 
 
P<0.001 
Mean P1NP (ng ml-1) 53.0 (20.7)(18) 17.6 (9.1)(18) P<0.001 
Mean TRAP5b (µg l-1) 2.37 (0.77)(18) 1.61 (0.17)(18) P=0.006 
Mean α/β CTX ratio 0.36 (0.15)(18) 0.25 (0.06)(18) P=0.016 
Table 5-4  Baseline bone marker results  
 
 
 
 
Figure 5-4   Regression coefficients for the treatment arm calculated by 
linear regression analysis on baseline bone marker results 
 
5.2.4 Bone densitometry 
Standardised BMD (sBMD) at the lumbar spine was statistically significantly 
higher in the treatment arm compared with the control arm on univariate 
analysis (p=0.006). This remained significant when age, AI use and 
menopausal status were added as variables to a linear regression model 
P1NP 
α/β CTX 
NTX 
TRAP5b 
0 0.2 0.4 0.6 0.8 1 1.2
ZOL regression coefficient 
p=0.012 
p<0.001 
p=0.026 
p<0.001 
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(p=0.035). At the hip, BMD was again statistically significantly higher in the 
treatment arm compared with the control arm on univariate analysis 
(p=0.018) and of borderline significance on linear regression (p=0.058). 
At the hip, the T-score for patients in the treatment arm was significantly 
higher when compared with patients in the control arm (0.30 versus -0.60; 
p=0.014). Similarly at the spine, the T-score for patients in the treatment arm 
was significantly higher when compared with patients in the control arm 
(0.15 versus -1.07; p=0.002). 
According to WHO classification, 72% of control patients and 84% of 
treatment arm patients had normal bone density at the hip. 50% of control 
patients and 83% of treatment arm patients had normal bone density at the 
spine. At the hip 28% of control patients were classified as osteopaenic 
compared with only 16% of treatment patients. At the spine, 44% of control 
patients were classified as osteopaenic compared with only 17% of 
treatment patients. Amongst the total cohort only 1 patient was classified as 
osteoporotic, their allocation was in the control arm.  
5.3 Follow up results 
5.3.1 Patient numbers 
29 scans were included in the 1-year analysis. Of the 37 patients who had 
baseline QBS, 3 patients relapsed and 4 declined to participate further in the 
study. A further 1 patient who underwent a 1-year QBS had invalid results 
that cannot be interpreted due to tissuing of tracer at the injection site and 
the scan was not repeated. Of the 29 patients who had a year 1 QBS, 3 
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further patients left the sub-study, 2 in the control arm and 1 in the treatment 
arm. Therefore, 26 scans were included in the 2-year analysis. 
 
5.3.2 Whole body Kbone/BMC   
Whole body Kbone/BMC was significantly suppressed at the 1-year follow 
up by Patlak plot method (p=0.003) and the modified Brenner method 
(p=0.011), and at 2-year follow up by the modified Brenner method 
(p=0.018) but not the Patlak method (p=0.100) (figure 5-5). Whole body 
Kbone/BMC was not significantly differently from baseline at 1 or 2 years of 
follow up amongst patients in the treatment arm. 
 
5.3.3 Kbone/BMC for skeletal ROIs 
Kbone/BMC remains significantly suppressed at the spine and pelvis at both 
1-year and 2-year follow up scans as calculated by Patlak plot method 
(p<0.001 for al results; figure 5-5). A trend is observed for increasing 
Kbone/BMC amongst treatment patients, becoming more similar to patients in 
the control arm, for the legs, arms and skull, however this does not reach 
statistical significance.  
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Figure 5-5   Plot displaying change in Kbone/BMC measured by Patlak 
analysis with time (x axis) and by treatment arm. Y axis represents 
coefficient for treatment with ZOL from linear regression analysis. P-
values related to vertical bars represent degree of significance from 
control group. P values related to horizontal bars represent 
significance in change of Kbone/BMC from baseline to 1 or 2 years in 
ZOL group. 
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5.3.4 Bone markers- follow up results 
NTX remained significantly suppressed in the treatment arm compared with 
the control arm at 6 months (p=0.014) and 2 years (p=0.005) of follow up, 
with a similar trend observed at 1 year that did not reach statistical 
significance (table 5-5). P1NP results displayed similar continued 
suppression through at 6 months (p=0.008), 1 year (p=0.053) and 2 years 
(p=0.049) of follow up. A trend for continued suppression at 2 years of follow 
up was also observed for TRAP5b and α/β CTX but did not reach statistical 
significance. 
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Bone marker Control (SD)(n) ZOL (SD)(n) Significance 
NTX  
Baseline  
6 month 
12 month 
24 month 
 
42.5 (17.6)(18) 
37.2 (16.0)(16) 
35.4 (13.4)(16) 
41.1 (20.2)(14) 
 
18.3 (6.2)(18) 
23.6 (12.7)(15) 
26.8 (10.0)(15) 
20.6 (8.9)(11) 
 
P<0.001 
P=0.014 
P=0.073 
P=0.005 
P1NP     
Baseline 53.0 (20.7)(18) 17.6 (9.1)(17) P<0.001 
6 month 
12 month 
24 month 
51.0 (24.5)(16) 
45.1 (16.3)(16) 
46.5 (21.8)(15) 
31.5 (10.9)(15) 
32.6 (17.5)(14) 
31.9 (15.5)(14) 
P=0.008 
P=0.053 
P=0.049 
TRAP5b      
Baseline 2.37 (0.77)(16) 1.61 (0.17)(13) P=0.006 
6 month 
12 month 
24 month 
2.00 (0.75)(16) 
2.30 (0.71)(15) 
2.56 (0.73)(16) 
2.07 (0.55)(11) 
1.79 (0.52)(13) 
1.84 (0.47)(14) 
P=0.795 
P=0.039 
P=0.071 
α/β CTX  
Baseline 
6 month 
12 month 
24 month 
 
0.36 (0.15)(14) 
0.34 (0.12)(13) 
0.38 (0.17)(13) 
0.32 (0.11)(13) 
 
0.25 (0.06)(14) 
0.25 (0.08)(12) 
0.26 (0.06)(13) 
0.24 (0.08)(13) 
 
P=0.016 
P=0.029 
P=0.034 
P=0.06 
Table 5-5   Baseline and follow up mean bone marker values by arm of 
study 
 
The plots in figure 5-6 show P1NP amongst the treatment arm significantly 
changes with time, the regression coefficient moving towards 1. This was 
statistically significant at both 1 year and 2 years of follow up. NTX shows a 
similar trend at 1 year however, at 2 years of follow up the regression 
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coefficient decreased again. TRAP5b and α/β CTX did not change 
significantly with time up to 2 years of follow up. 
 
 
Figure 5-6  Change in bone markers with time (x axis) and by treatment 
arm. Y axis represents coefficient for treatment with ZOL from linear 
regression analysis (ZOL regression coefficient). P-values related to 
vertical bars represent degree of significance from control group. P-
values related to horizontal bars represent significance in change of 
markers from baseline to 12 or 24 months in ZOL group. 
 
5.3.5 Bone densitometry 
At 1 year of follow up, mean sBMD at the lumbar spine had increased from 
baseline in the control group and decreased in the treatment arm. The 
difference between the 2 groups was significant at 1 year (p=0.038; figure 5-
7). By 2 years of follow up the control group mean sBMD continued to 
increase from baseline to 1.6%, while mean sBMD had decreased from 
baseline in the treatment arm by -1.3%. At 2 years this difference was no 
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Figure 5-7  Mean percentage change in sBMD from baseline at 1 year 
and 2 years follow up. Error bars show 95% confidence interval for 
lumbar spine and hip. 
longer statistically significant (p=0.137). At the hip there was an observed 
mean decrease in sBMD from baseline in both treatment arms at 1 year and 
2 years. The sBMD changes at the hip were not statistically different at 
either 1 or 2 years of follow up. 
- 165 - 
5.4 Discussion 
The present study confirmed that, following 5 years of ZOL, Kbone and 
Kbone/BMC were significantly suppressed compared with the control group. 
Of particular interest, there was evidence that this suppression was not 
uniform throughout the skeleton and that the axial skeleton (pelvis and 
spine) may be more suppressed than the appendicular skeleton (arms and 
legs). Indeed, even after 5 years of ZOL, the Kbone/BMC of the legs was not 
significantly different from that in the control group.  This may be explained 
by the greater extent of trabecular bone in the axial skeleton, which is more 
influenced by ZOL and a greater impact of the drug was seen here.  
The methodology used in this study provides us with greater information 
about the effect of ZOL on bone turnover than can be generated by bone 
markers or iliac crest bone biopsies and is a particularly novel aspect. Such 
a complex dynamic investigation has not previously been undertaken in a 
population of this size, nor in a population of early breast cancer patients 
with a control group for comparison. Furthermore, identifying suppression in 
regions of the skeleton in addition to the whole skeleton and normalising to 
bone mineral content has not previously been published and is a unique 
aspect of the study. Bone markers supported the QBS findings at baseline, 
were all significantly suppressed in the treatment arm compared with 
controls. This was most profound in the conventional turnover markers, NTX 
(resorption) and P1NP (formation).  
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BMD and T-scores at baseline were additionally significantly higher in the 
treatment arm compared with controls. This is an expected result but 
reassuring to confirm given the small numbers of subjects in this sub-study.  
We believe that Kbone/BMC gives us the most reliable estimate of skeletal 
plasma clearance of tracer given that it corrects for the differences in the 
mass of bone mineral in each sub-region of the skeleton. Using these 
calculations, by 1 year the treatment arm remained significantly suppressed 
compared with the control arm. Again, there was a differential effect across 
the regions. Only spine Kbone/BMC and pelvis Kbone/BMC remained 
significantly suppressed compared to controls. The other regions followed a 
similar trend but are approaching the levels seen in the control group.  
Whilst still significantly suppressed compared to controls, the trend was that 
between baseline and 1 year, the WB Kbone/BMC measurements in the 
treatment arm did rise, approaching the levels seen in the control group. 
Bone markers were also increased at 6 and 12 months compared with 
baseline in the treatment arm. These findings indicate that the degree of 
suppression among the treatment arm patients was wearing off, but the 2 
groups did remain significantly different from each other at 12 months 
(P1NP, TRAP5b, α/β CTX). 
 
The trends were similar at 2 years. WB Kbone/BMC and the bone markers all 
increased from baseline, reflecting reduced degree of suppression in the 
treatment arm. However, the suppressing effect of ZOL was still seen at 2 
years when compared with the control arm, particularly Kbone/BMC spine and 
pelvis and bone markers (NTX and P1NP).   
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This study has shown that it is possible to recruit to interventional studies 
that are relatively complex and time-consuming for patients. However, there 
are some weaknesses identified. This sub-study successfully consented 40 
patients to participate, achieving the sample size goal as per protocol and 
allowing confidence in the statistical interrogation of the data. 2 patients from 
the total sub-study cohort were identified at baseline as having relapse with 
bone metastases and therefore were excluded. There was a good balance 
of numbers between the control and treatment arms. However, by 1 year 
there were only 29 scans for analysis, due to drop out and relapse, and only 
26 by 2 years. Our statistical analysis plan allowed for a 25% drop out, but 
this underestimated the actual number. It is possible that given greater 
numbers of subjects, some of the trends seen in this study may have 
reached statistical significance.  
Another weakness was the different bone scan tracer used at the 2 sites. 
Whilst each of the individual tracers is adequate for performing the QBS, 
their detailed kinetics are different. Consequently, the patient investigations 
performed with MDP were not directly comparable with those performed with 
HMDP, requiring a statistical model that allowed for this discrepancy. 
Uniform use of tracer across both sites would have been preferable. This 
was not a problem when patients are used as their own controls, i.e. when 
investigating change over time and the data are paired. However, where 
necessary, data have been displayed separately, by tracer and arm. We 
have shown that HMDP consistently results in higher Kbone results than MDP 
by approximately 20-30%. For example, baseline WB Kbone as measured by 
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the modified Brenner method was 34.3 mls min-1 for HMDP compared with 
28.7 mls min-1 for MDP, amongst the control group. This trend was seen 
throughout the skeleton and is displayed in figure 5-1 and figure 5-3B.  
At baseline suppression was identified in Kbone in the mandible and 
calvarium. However, as it was not possible to collect BMC data for these 
regions, the analysis here was more limited. Furthermore, the drawing of 
these ROIs was particularly subjective and subject to great variation, 
resulting in less reliable data.  
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Final discussions 
The entirety of the work in this thesis involved participants in the large 
randomised phase III AZURE trial. The efficacy data was most recently 
published in 2014 and demonstrates no overall benefit from the addition of 
zoledronic acid to standard adjuvant treatments for early breast cancer (HR 
0·94, 95% CI 0·82-1·06; p=0·30)182. However, there is continued 
demonstration that zoledronic acid reduces bone metastases at any time 
(HR 0.81, 0·68-0·97; p=0·022) and  improved IDFS in those who were over 
5 years since menopause at trial entry (n=1041; HR 0·77, 95% CI 0·63-
0·96). The study was incorporated into a meta-analysis of adjuvant 
bisphosphonates in early breast cancer (n = 18, 766) and concludes that the 
reduction in bone recurrence was convincing (HR 0·83, 0·73-0·94; p=0·004) 
and that for women who were postmenopausal at study entry, there were 
significant reductions in recurrence (RR 0·86, 95% CI 0·78-0·94; p=0·002), 
distant recurrence (0·82, 0·74-0·92;p=0·0003), bone recurrence (0·72, 0·60-
0·86; 2p=0·0002), and breast cancer mortality (0·82, 0·73-0·93; p=0·002). 
249. Adjuvant bisphosphonates have now been introduced as a standard of 
care and recommended in UK, European and American guidelines. The 
safety data in my thesis has contributed to the uptake of adjuvant 
bisphosphonates among UK and global oncologists (70% uptake amongst 
UK oncologists, personal communication). The UK Breast Cancer Group 
recommends i.v. bisphosphonates whilst on chemotherapy followed by 3 
years of the oral bisphosphonate ibandronate, with calcium and vitamin D. It 
remains unknown the duration needed for benefit or, to what extent benefit 
reduces on stopping bisphosphonates. 
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The primary purpose of the QBS sub-study was to determine if there are any 
negative consequences of 5 years adjuvant zoledronic acid. We have shown 
that bone turnover remains significantly suppressed 2 years after the 
cessation of the bisphosphonate, most profoundly in the axial skeleton. The 
protocol design is a 5 year study and the data for the 5 year time point is 
now available for analysis, interpretation and preparation for 
presentation/publication. It is likely that if the QBS sub-study was being 
designed today it would be designed using hybrid positron emission 
tomography and computed tomography (PET/CT) dual modality system with 
the bone-imaging agent [18F]NaF, rather than the gamma camera. PET 
imaging with [18F]NaF is now recognised as the optimum radionuclide 
imaging technique for the investigation of metastatic and metabolic bone 
disease due to the tracers superior bone-seeking properties with 
exceptionally high and rapid uptake into bone, rapid clearance from soft 
tissue and absence of any protein binding250.    
It is important to note that practice has changed significantly since AZURE 
was actively recruiting patients. In the initial phase of the study HER2 testing 
was not routinely carried out, where it is now a standard alongside ER and 
PR. Additional molecular testing is available to tailor treatment to a particular 
genetic profile, such as Oncotype, which has been widely taken up and 
changed decision making in early breast cancer. Emerging therapies in 
breast cancer, such as immunotherapy, are likely to change this even further 
and it is likely that the pattern of disease will consequently change. However, 
it is right that efforts continue to be made in the search for bone-modifying 
agents to ease the significant burden of this disease. 
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Appendix 4 
WHO Risk factor Questionnaire 
 
What is your date of birth?  __/__/____ 
 dd mm yyyy 
 
How tall are you?   ___ ft and ___ inches OR ___ cm 
 
How much do you weigh?   ___ stones and ___ pounds OR ___ kg 
 
 
Answer the following questions by circling the appropriate response: 
 
Have you ever broken a bone after the age of 50 
years that resulted from a low level of injury (e.g. a 
simple fall from standing height)? 
 
Yes / No / Don’t know 
Have you ever taken glucocorticoids (steroids) (e.g. 
prednisolone) by tablets or suppository for more 
than a few weeks? 
Yes / No / Don’t know 
Have either of your parents ever broken a hip 
following a low level of injury (e.g. a fall from 
standing height)? 
Yes / No / Don’t know 
Have you ever been diagnosed with rheumatoid 
arthritis (not osteoarthritis)? 
Yes / No / Don’t know 
On average, do you drink 3 or more units of alcohol 
(1 unit=1/2 pint of beer or 1 glass of wine or 1 short 
measures of spirits) each day? 
 
Yes / No / Don’t know 
Are you a smoker? Yes / No  
 
Other conditions: Please tick the box beside any of the conditions listed 
below if they have or do affect you personally: 
Menopause or prolonged absence of your periods (other than pregnancy) 
before age 45   
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Longstanding poor mobility (e.g. following a stroke, Parkinson’s disease, 
spinal injury)    
Crohn’s Disease or Ulcerative Colitis   Major organ transplant  
Insulin-dependent diabetes   Overactive thyroid gland  
Coeliac disease     
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